CN105188766B - 生物活性分子、其偶联物及治疗用途 - Google Patents
生物活性分子、其偶联物及治疗用途 Download PDFInfo
- Publication number
- CN105188766B CN105188766B CN201480025356.9A CN201480025356A CN105188766B CN 105188766 B CN105188766 B CN 105188766B CN 201480025356 A CN201480025356 A CN 201480025356A CN 105188766 B CN105188766 B CN 105188766B
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- cancer
- antibody
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000975 bioactive effect Effects 0.000 title abstract description 45
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 236
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 230000002159 abnormal effect Effects 0.000 claims abstract description 22
- 230000010261 cell growth Effects 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 96
- 229940024606 amino acid Drugs 0.000 claims description 72
- 235000001014 amino acid Nutrition 0.000 claims description 72
- 150000001413 amino acids Chemical group 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 229960001230 asparagine Drugs 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000000611 antibody drug conjugate Substances 0.000 claims description 20
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229960004295 valine Drugs 0.000 claims description 15
- 239000004474 valine Substances 0.000 claims description 15
- 229910021529 ammonia Inorganic materials 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 229940088598 enzyme Drugs 0.000 claims description 13
- 229960003767 alanine Drugs 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 229960002173 citrulline Drugs 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229960001153 serine Drugs 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 229960002433 cysteine Drugs 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 235000008729 phenylalanine Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- 102000005600 Cathepsins Human genes 0.000 claims description 3
- 108010084457 Cathepsins Proteins 0.000 claims description 3
- 108010088842 Fibrinolysin Proteins 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 229940001501 fibrinolysin Drugs 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- 235000002374 tyrosine Nutrition 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 63
- 239000003446 ligand Substances 0.000 abstract description 39
- 230000008859 change Effects 0.000 abstract description 9
- 239000002585 base Substances 0.000 description 131
- 125000003118 aryl group Chemical group 0.000 description 101
- 125000001072 heteroaryl group Chemical group 0.000 description 98
- 125000000623 heterocyclic group Chemical group 0.000 description 96
- 125000001424 substituent group Chemical group 0.000 description 91
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 79
- 125000003342 alkenyl group Chemical group 0.000 description 73
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
- 125000000304 alkynyl group Chemical group 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000007787 solid Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- -1 pseudomonad Proteins 0.000 description 34
- 229930126263 Maytansine Natural products 0.000 description 33
- 239000000562 conjugate Substances 0.000 description 33
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 33
- 238000010168 coupling process Methods 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 230000008878 coupling Effects 0.000 description 29
- 238000005859 coupling reaction Methods 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 150000001345 alkine derivatives Chemical class 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 16
- 238000012545 processing Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 14
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 14
- 125000002252 acyl group Chemical group 0.000 description 13
- 230000003833 cell viability Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- 230000001028 anti-proliverative effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229960005558 mertansine Drugs 0.000 description 11
- 239000000376 reactant Substances 0.000 description 11
- 102000004225 Cathepsin B Human genes 0.000 description 10
- 108090000712 Cathepsin B Proteins 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 10
- 239000003120 macrolide antibiotic agent Substances 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 229910052737 gold Inorganic materials 0.000 description 9
- 239000010931 gold Substances 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 229920001971 elastomer Polymers 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 6
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- NDDSIUHFLJACFT-VWURTLBMSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,4-diamino-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 NDDSIUHFLJACFT-VWURTLBMSA-N 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 5
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 5
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000005373 pervaporation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 241000432824 Asparagus densiflorus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 description 4
- HZYHBDVRCBDJJV-HAFWLYHUSA-N Ile-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O HZYHBDVRCBDJJV-HAFWLYHUSA-N 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102100029000 Prolactin receptor Human genes 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000007541 cellular toxicity Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- RBVWUBLKKPXRTQ-FMEGDIDESA-N N[C@@H](CC(N)=O)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O Chemical compound N[C@@H](CC(N)=O)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O RBVWUBLKKPXRTQ-FMEGDIDESA-N 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012990 dithiocarbamate Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 2
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical class CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102100035139 Folate receptor alpha Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010129 solution processing Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229930013292 trichothecene Natural products 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
- UGCWVVMCHYLGBO-DQZFIDPSSA-N (2s,3s)-2-amino-3-methylpentanoic acid;(2s)-2,4-diamino-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(N)=O UGCWVVMCHYLGBO-DQZFIDPSSA-N 0.000 description 1
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 description 1
- LMGGOGHEVZMZCU-FGJMKEJPSA-N (2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-2-carboxylic acid Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(O)=O)C1 LMGGOGHEVZMZCU-FGJMKEJPSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LDNCWSAHVWXJNF-ZEELXFFVSA-N 2-(3-aminopropyl)-1-[(e)-[(2e)-2-[[n'-(3-aminopropyl)carbamimidoyl]hydrazinylidene]ethylidene]amino]guanidine Chemical compound NCCCN=C(N)N\N=C\C=N\NC(N)=NCCCN LDNCWSAHVWXJNF-ZEELXFFVSA-N 0.000 description 1
- UHOIFEOHBGCPHE-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1h-isoquinoline-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=C1 UHOIFEOHBGCPHE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical class OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 102100021222 ATP-dependent Clp protease proteolytic subunit, mitochondrial Human genes 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 102100036526 Anoctamin-7 Human genes 0.000 description 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- MDKCFLQDBWCQCV-UHFFFAOYSA-N Benzyl isothiocyanate Natural products S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 101150108242 CDC27 gene Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000723375 Colchicum Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- WQOXQRCZOLPYPM-UHFFFAOYSA-N Dimethyl disulfide Natural products CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 101150049307 EEF1A2 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 description 1
- 101710144640 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000750222 Homo sapiens ATP-dependent Clp protease proteolytic subunit, mitochondrial Proteins 0.000 description 1
- 101000928370 Homo sapiens Anoctamin-7 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 description 1
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 1
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 102100026181 Placenta-specific protein 1 Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 102100040682 Platelet-derived growth factor D Human genes 0.000 description 1
- 101710170209 Platelet-derived growth factor D Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 description 1
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100026160 Tomoregulin-2 Human genes 0.000 description 1
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000015979 Uroplakin-3 Human genes 0.000 description 1
- 108050004262 Uroplakin-3 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OMWQUXGVXQELIX-UHFFFAOYSA-N bitoscanate Chemical compound S=C=NC1=CC=C(N=C=S)C=C1 OMWQUXGVXQELIX-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229950007271 boldenone Drugs 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical class [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- OFHVTRBJIUUZIM-UHFFFAOYSA-N n-[4-(isothiocyanatomethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(CN=C=S)C=C1 OFHVTRBJIUUZIM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- OYSMISPYDVWGPI-UHFFFAOYSA-N oxane thiophene Chemical compound O1CCCCC1.S1C=CC=C1 OYSMISPYDVWGPI-UHFFFAOYSA-N 0.000 description 1
- 101800000607 p15 Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 230000007281 self degradation Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RAGFPHFDFVNLCG-INYQBOQCSA-N sibiromycin Chemical compound O[C@@H]1[C@@](O)(C)[C@@H](NC)[C@H](C)O[C@H]1OC(C(=C1O)C)=CC(C2=O)=C1N[C@H](O)[C@H]1N2C=C(\C=C\C)C1 RAGFPHFDFVNLCG-INYQBOQCSA-N 0.000 description 1
- RAGFPHFDFVNLCG-UHFFFAOYSA-N sibiromycin Natural products OC1C(O)(C)C(NC)C(C)OC1OC(C(=C1O)C)=CC(C2=O)=C1NC(O)C1N2C=C(C=CC)C1 RAGFPHFDFVNLCG-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 101150050955 stn gene Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 229930184737 tubulysin Natural products 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D507/00—Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D505/00; Such ring systems being further condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及用于共价连接生物活性分子和配体的连接体化合物。所公开的化合物还涉及生物活性分子和配体偶联物,其中所述生物活性分子通过连接体与配体连接。本发明还提供包括生物活性分子‑配体偶联物的组合物、使用所述偶联物或组合物来改变异常细胞生长的方法和治疗方法。
Description
技术领域
本发明提供了配体-生物活性分子偶联物,其中所述配体与生物活性分子通过连接体(linker)化合物相连接。本发明还提供了用于各种治疗应用的药物组合物中的偶联化合物。
发明背景
增殖性疾病具有异常细胞的不受控生长和扩散的特点。如果扩散不受控制,它会导致死亡。异常增殖(例如,癌症)是由外部因素(例如,烟草、化学品、辐射和感染性生物体)和内部因素(遗传突变、免疫系统条件、由代谢发生的突变)引起的。这些致病因素可以共同作用或依次作用而引发或促进异常增殖。癌症通过手术、放疗、化疗、激素和免疫疗法进行治疗。然而,对更有效的抗增殖药物仍有需求。
理想的抗增殖治疗能够对肿瘤细胞靶向输送高细胞毒性剂,并将使正常细胞不受影响。传统的化疗治疗,以美登素为例,由于该药物对非癌细胞的作用所引起的毒副作用而受限。对靶向给药已经尝试了各种方法,包括使用肿瘤靶向探针(诸如抗体或生长因子)与毒素的偶联物,所述毒素如假单胞菌、白喉毒素,其阻止蛋白质和细胞的合成。然而,由于偶联物的非人成分,其副作用包括免疫系统的反应。此外,由于通过肾脏过滤及示意性降解从循环中消除、被网状内皮系统(RES)吸收、和在非靶向的器官和组织中的累积,使得药物偶联物的半衰期受限。
另一种方法使用被动药物载体(诸如聚合物、脂质体和聚合物胶束)以利用肿瘤组织血管内皮的高渗透性。由于渗透性增强和保留机制,高分子药物和大分子积累在实体瘤内。然而,使用这种靶向递送的障碍包括快速清除血液中的外来粒子,以及获得高度标准化,药学上可接受的药物输送系统的技术障碍,所述药物输送系统对结合肿瘤细胞具有必要的特异性和选择性。
因此,对靶向抗增殖化合物存在需要。
发明内容
本发明涉及由以下结构式(I)所表示的偶联化合物:
其中:
L不存在或是配体;
进一步其中:
当L是配体时,L能够结合细胞或细胞群;
a是从1到10的整数;
Z2和Z1各自独立不存在或是间隔基;
D是生物活性分子;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-、-NR4-;
进一步其中:R4、R5和R6各自独立是H、或具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基;
X不存在,或是芳基、杂芳基、环烷基、杂环基,其中芳基、杂芳基、环烷基和杂环基可选地具有取代基;和
Y不存在,或是间隔基。
本发明还提供了由以下结构式(V)表示的连接体生物活性化合物:
Z2-A-W-X-Y-Z1-D (v)
其中:
Z2和Z1各自独立不存在或是间隔基;
D是生物活性分子;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-、-NR4-;
进一步其中:R4、R5和R6各自独立是H,或具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基;
X不存在,或是芳基、杂芳基、环烷基、杂环基,其中芳基、杂芳基,环烷基和杂环基可选地具有取代基;和
Y不存在,或是间隔基。
本发明还提供了由以下结构式(VI)表示的连接体。
在一实施方案中,由式(VI)表示连接体化合物:
Z2-A-W-X-Y-Z1 (VI)
其中:
Z2和Z1各自独立不存在或是间隔基;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-、-NR4-;
X不存在,或是芳基、杂芳基、环烷基、杂环基,其中芳基、杂芳基、环烷基和杂环基可选地具有取代基;
Y不存在,或是
其中A1、A3、R1和R3各自独立地是不存在、氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-S-C(=S)-、-C(=S)-NH-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
A4和A5各自独立是-O-、-S-、-NR18-、-CR5R6-;
R17选自由O、S、NR18、CR5R6构成的组;
R18选自由H、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基构成的组,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基可选地具有取代基;
R4、R5、R6和R8各自独立是H,或具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基;
p1、p2和p3各自独立是0或1-100的整数;和
x是0、1或2。
在一方面,本发明提供了具有式(VI)的化合物,其中Z2由以下结构式表示:
-Z2A-Z2B-Z2C-Z2D-,
其中:
Z2A、Z2B、Z2C和Z2D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基和杂环基。
本发明还涉及药物组合物,其包括:治疗有效量的具有式(I)的化合物或其药学上可接受的盐,以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
本发明还提供了减少、延缓或阻止异常细胞生长的方法,其包括使具有式(I)的化合物(具有足以延缓、减少或阻止异常细胞生长的量)与异常细胞相接触,并且其中所述异常细胞生长被延缓,减少或阻止。
本发明还提供了杀死细胞的方法,其包括使具有式(I)的化合物(具有足以杀死细胞的量)与细胞相接触,并且其中所述细胞被杀死。
本发明还提供了对患有医学病症的个体的医学病症治疗方法,其包括将有效量的组合物施用至个体,所述组合物包含具有式(I)的化合物。
本发明还提供了在有需要的个体内减少肿瘤尺寸、阻止肿瘤尺寸增加、减少肿瘤增殖、或防止肿瘤增殖的方法,其包括将有效量的组合物施用至个体以减少肿瘤尺寸、阻止肿瘤尺寸增加、减少肿瘤增殖、或防止肿瘤增殖,其中所述组合物包括具有式(I)的化合物。
本发明还涉及由式(V)表示的前体生物活性分子-连接体化合物。具有式(V)的化合物为具有式(I)的偶联化合物提供了结构单元。此外,所述具有式(V)的化合物可以作为组合物、药物组合物及其药学上可接受的盐被提供。
本发明进一步包括所述组合物中的任一组合物在制造用于治疗、预防和/或改善医学病症的药剂中的用途,所述组合物包括具有式(I)的化合物和/或药物制剂。
本发明进一步包括所述组合物中的任一组合物在制造用于治疗、预防和/或改善肿瘤的药剂中的用途,所述组合物包括具有式(I)的化合物和/或药物制剂。
附图说明
图(1-8)描述了细胞活力(cell viability)试验的结果,在该试验中,各种癌细胞系在体外生长并且经过所示的抗体、游离药物或抗体-药物偶联物的连续稀释液处理。存活百分比根据实施例14中阐述的方法来确定。
图1A显示经过化合物2、偶联到化合物3的同种型对照抗体(“同种型对照-3”)、偶联到化合物3的抗PSMA抗体(“PSMA-3”)、以及未偶联的抗PSMA抗体(“PSMA”)处理后的C4-2细胞(前列腺癌细胞系)的细胞活力结果。
图1B显示经过化合物6、偶联到化合物7的同种型对照抗体(“同种型对照-7”)、偶联到化合物7的抗PSMA抗体(“PSMA-7”)、以及未偶联的抗PSMA抗体(“PSMA”)处理后的C4-2细胞(前列腺癌细胞系)的细胞活力结果。
图1C显示经过化合物25、偶联到化合物21的同种型对照抗体(“同种型对照-21”)、偶联到化合物21的抗PSMA抗体(“PSMA-21”)、以及未偶联的抗PSMA抗体(“PSMA”)处理后的C4-2细胞(前列腺癌细胞系)的细胞活力结果。
图2显示了经过化合物6、偶联到化合物7的同种型对照抗体(“同种型对照-7”)、偶联到化合物7的抗STEAP1抗体(“STEAP1-7”)、以及未偶联的抗STEAP1抗体(“STEAP1”)处理后的PC3/hSTEAP1细胞(表达外源hSTEAP1的前列腺癌细胞系)的细胞活力结果。
图3显示了经过化合物6、偶联到化合物7的同种型对照抗体(“同种型对照-7”)、偶联到化合物7的抗PRLR抗体(“PRLR-7”)、以及未偶联的抗PRLR抗体(“PRLR”)处理后的T47D细胞(乳腺癌细胞系)的细胞活力结果。
图4显示了经过化合物6、偶联到化合物7的同种型对照抗体(“同种型对照-7”)、偶联到化合物7的抗EGFRvIII抗体(“EGFRvIII-7”)、以及未偶联的抗EGFRvIII抗体(“EGFRvIII”)处理后的HEK293/hEGFRvIII细胞(表达外源hEGFRvIII的HEK293细胞)的细胞活力结果
图5显示了经过化合物6、偶联到化合物7的同种型对照抗体(“同种型对照-7”)、偶联到化合物7的抗EGFRvIII抗体(“EGFRvIII-7”)、以及未偶联的抗EGFRvIII抗体(“EGFRvIII”)处理后的MMT/hEGFRvIII细胞(表达外源hEGFRvIII的MMT细胞)的细胞活力结果。
图6显示了经过化合物6、偶联到化合物7的同种型对照抗体(“同种型对照-7”)、偶联到化合物7的抗EGFRvIII抗体(“EGFRvIII-7”)、以及未偶联的抗EGFRvIII抗体(“EGFRvIII”)处理后的U251/hEGFRvIII细胞(表达外源hEGFRvIII的U251细胞)的细胞活力结果。
图7,板A和B分别显示了经过化合物6、27、29和31(均为未偶联的)处理的HEK293和U87MG细胞的细胞活力结果。
图8,板A-E分别显示了经过化合物6、9、33和35(均为未偶联的)处理的HEK293、U251、C4-2、PC3和MMT细胞的细胞活力结果。
具体实施方式
在下列说明中对某些实施方案做出的引用被认为仅是对公开内容原理的说明。此外,由于大量的修改和更改对本领域技术人员来说将是显而易见的,因此其没有试图限制公开内容至本文中描述的示出的精确构造和过程。因此,所有适当的修改及其等同物可以落入本公开的范围内,并由所附的权利要求限定。
当在本说明书中以及在以下列权利要求中使用词语“包括”、“含有”、“包含”、“具有”(“comprise”、“comprising”、“include”和“including”)时,其意旨于指定所述的特征、整数、组件或步骤的存在,但它们不排除其一个或多个额外特征、整数、组件或步骤的存在或增加。
在本发明任意实施方案中所用的一般术语可以被定义如下;然而,所述的含义不应被解释为限制术语本身的范围。
本文所用的术语“偶联物”是指具有配体、连接体和生物活性分子的化合物。示例性的例子包括具有式(Ⅰ)、(Ⅲ)和(Ⅳ)的化合物。
本文所用的术语“间隔基”是指用于将配体从生物活性分子进行空间分开以及允许细胞内连接体分解代谢的连接体的化学结构单元。间隔基可以由Z1和Z2表示。
本文所用的术语“大环内酯”是指具有大环内酯环的任意生物活性分子。
本文所用的术语“烷基”是指具有通式CnH2n+1的烃基。烷基的例子包括:甲基、乙基、1-丙基、2-丙基、1-丁基等。典型的烷基具有从1到10个碳原子、1到9个碳原子、1到8个碳原子、1到7个碳原子、1到6个碳原子、1到5个碳原子、1到4个碳原子、1到3个碳原子、1到2个碳原子或1个碳原子。
本文所用的术语“芳基”是指通常有6到18个碳原子的一价或多环芳香烃。芳基的例子包括苯基(如苯)、取代的苯、萘、蒽、茚基、四氢萘基等。
本文所用的术语“烯基”是指具有两个或多个碳原子的脂肪族直链或支链的一价烃基,其至少有一个位点不饱和。烯基有通式R2C=CR2。烯基的例子包括:乙烯基(ethylenyl)、乙烯基(vinyl)、烯丙基等等。
本文所用的术语“炔基”是指包含三键的一价脂肪族烃基。典型的炔基具有2个到20个碳原子(并且包括至少一个三键)。烯基的例子包括乙炔基、丙炔基、1-丁炔基、2-丁炔基、1-戊炔基、己炔基等。
本文所用的术语“环烷基”是指一价饱和碳环基。典型的环烷基是3-7元单环基。环烷基的一个例子是环己基。
本文所用的术语“杂芳基”是指5或6元环的一价芳香基。杂芳基包括具有多达5-18个碳原子的稠环系统(至少一个必须为芳族的),其含有一个或多个独立选自氮、硫或氧的杂原子。例证型杂芳基是吡啶基、三唑基、呋喃基、吡嗪基、噻吩基、异恶唑基、吲唑基、呋吖基、苯并噻唑基,喹唑啉基和呋喃并吡啶基。
本文所用的术语“杂环基”是指通常具有3-18个碳原子的饱和或部分饱和的碳环基,其中至少一个环原子是选自氮,氧,磷和硫的杂原子。例如,杂环基可能是单环或二环。杂环基的例子是吡咯烷基(pyrolidinyl)、四氢呋喃基、二氢吡喃基、噻噁烷基(thioxanyl),2H-吡喃基、二噁烷基、二噻烷基、哌啶基等。
本文所用的短语“药学上可接受的盐”是指本文所描述的偶联化合物的有机和无机盐,例如,具有式(I)、(III)、(IV)和(V)的化合物。所述盐是药学上可接受的并且包括:硫酸盐、柠檬酸、硝酸盐、磷酸盐、抗坏血酸盐、溴化盐、葡萄糖酸盐、苯甲酸盐、草酸盐、泛酸盐等。要注意的是本文中药学上可接受的盐在其结构中可包含多于1个的带电原子以及一个或多个反荷离子。本文将偶联化合物制备为药学上可接受的盐是本领域技术人员所熟知的。
本文所用的术语“人类抗体”意旨于包括来源于人类免疫球蛋白序列的具有可变区和恒定区的抗体。本发明的人类mAbs可包括不由人免疫球蛋白序列编码的氨基酸残基(例如,通过体外随机或位点特异性的突变形成或通过体内体细胞突变引起的突变),例如在CDRs中,且尤其是CDR3中。然而,本文所用的术语“人类抗体”不意旨于包括mAbs,所述mAbs中的CDR序列来源于被移植到人类的FR序列上的另一种哺乳动物物种的生殖细胞系(germline)。
本文所用的术语“治疗有效量”是指施用后能够产生预期效果的量。准确的量将取决于治疗的目的,并将由本领域技术人员使用已知技术来确定(例如参见,Lloyd(1999)TheArt,Science and Technology of Pharmaceutical Compounding)。
配体和结合伴侣
本文所描述的偶联化合物实施方案的有效性取决于配体对结合其配体结合伴侣的选择性。
在一个实施方案中,配体是在哺乳动物体内能够与给定的结合伴侣特异性结合的任何分子,其中该相互作用可以产生治疗用途。在某些方面所述配体能够结合到细胞或细胞群上。
本文供使用的配体包括抗体、淋巴因子、激素、生长因子、病毒受体、白介素、或任何其它细胞结合或肽结合分子或物质。
在一个实施例中,所述配体是抗体。如本文所定义的,抗体是指单克隆抗体、多克隆抗体、抗体片段(Fab、Fab’和F(ab)2,微抗体、双抗体、三抗体等)以及双特异性抗体。本文中的抗体可使用美国专利(专利号6,596,541)和美国公开号2012/0096572描述的方法来进行人源化,其各自以其整体通过引用并入本文。
当配体是抗体时,它与抗原结合伴侣相结合,所述抗原结合伴侣是多肽并且可为跨膜分子(例如,受体)或生长因子。典型的抗原包括但不限制于,诸如肾素分子;生长激素,包括人类生长激素和牛生长激素;生长激素释放因子;甲状旁腺激素;促甲状腺激素;脂蛋白;α1-抗胰蛋白酶;胰岛素A链;胰岛素B链;胰岛素原;促卵泡激素;降钙素;促黄体激素;胰高血糖素;诸如vmc因子、IX因子、组织因子(TF)和血管性血友病因子等凝血因子;诸如蛋白C等抗凝血因子;心钠素;肺表面活性物质;纤溶酶原激活剂,诸如尿激酶或人尿液或组织型纤溶酶原激活剂(t-PA);蛙皮素;凝血酶;造血生长因子;肿瘤肿瘤坏死因子-α和β;脑啡肽酶;RANTES(调节激活正常T细胞表达和分泌);人巨噬细胞炎性蛋白(M1P-I-α);血清白蛋白,诸如人血清白蛋白;苗勒(Muellerian)-抑制物质;松弛素A链;松弛素B链;松弛素;小鼠促性腺激素相关肽;微生物蛋白,诸如β内酰胺酶;DNase;19E;细胞毒性T淋巴细胞相关抗原(CTLA),诸如CTLA-4;抑制素;激活素;血管内皮生长因子(VEGF);激素或生长因子受体;蛋白A或D;类风湿因子;神经营养因子如骨源性神经营养因子(BDNF),神经营养因子-3、-4、-5、或-6(NT-3、NT4、NT-5或NT-6),或神经生长因子诸如NGF-β;血小板源生长因子(PDGF);诸如aFGF和bFGF等的成纤维细胞生长因子;纤维原细胞生长因子受体2(FGFR2),表皮生长因子(EGF);转化生长因子(TGF),如TGF-α和TGF-β,包括TGF-β1、TGF-β2、TGF-β3、TGF-β4或TGF-β5;胰岛素样生长因子-1和-II(IGF-1和IGF-II);des(1-3)-IGF-1(脑IGF-1),胰岛素样生长因子结合蛋白,EpCAM,GD3,FLT3,PSMA,PSCA,MUCI,MUCI 6,STEAP,CEA,TENB2,EphA受体,EphB受体,叶酸受体,FOLR1,间皮素,cripto,alphavbeta6,整合素,VEGF,VEGFR,EGFR,转铁蛋白受体,lRTAI,lRTA2,lRTA3,lRTA4,lRTA5;CD蛋白如CD2、CD3、CD4、CD5、CD6、CD8、CDII、CDI4、CDI9、CD20、CD21、CD22、CD25、CD26、CD28、CD30、CD33、CD36、CD37、CD38、CD40、CD44、CD52、CD55、CD56、CD59、CD70、CD79、CD80、CD81、CD103、CD105、CD134、CD137、CD138、CDI52,或与一种或多种肿瘤相关抗原或细胞表面受体相结合的抗体,其在美国公开号2008/0171040或美国公开号2008/0305044中公开,并且其整体通过引用并入本文;促红细胞生成素;骨诱导因子;免疫毒素;骨形态生成蛋白(BMP);干扰素,如干扰素-α,-β和-γ;集落刺激因子(CSFs),例如,M-CSF、GM-CSF和G-CSF;白介素(IL),例如,IL-1至IL-10;超氧物歧化酶;T细胞受体;表面膜蛋白;衰变加速因子;病毒抗原,例如,对HIV包膜的部分;转运蛋白;归巢受体;地址素;调节蛋白;整合素,诸如CDlla,CDllb,CDllc,CDI8,ICAM,VLA-4和VCAM;肿瘤相关抗原诸如AFP,ALK,B7H4,BAGE蛋白,β-连环蛋白,brc-abl,BRCA1,BORIS,CA9(碳酸酐酶IX),CD20,CD40,CD123,CDK4,CEA,CLEC12A,c-kit,cMET,CTLA4,细胞周期素-B1,CYP1B1,EGFR,EGFRvIII,内皮因子,Epcam,EphA2,ErbB2/Her2,ErbB3/Her3,ErbB4/Her4,ETV6-AML,Fra-1,FOLR1,GAGE蛋白质(例如,GAGE-1,-2),GD2,GD3,GloboH,磷脂酰肌醇聚糖-3,GM3,gp100,Her2,HLA/B-raf,HLA/EBNA1,HLA/k-ras,HLA/MAGE-A3,hTERT,IGF1R,LGR5,LMP2,MAGE蛋白质(例如,MAGE-1、-2、-3、-4、-6、和-12),MART-1,间皮素,ML-IAP,Muc1,Muc16(CA-125),MUM1,NA17,NGEP,NY-BR1,NY-BR62,NY-BR85,NY-ESO1,OX40,p15,p53,PAP,PAX3,PAX5,PCTA-1,PDGFR-α,PDGFR-β,PDGF-A,PDGF-B,PDGF-C,PDGF-D,PLAC1,PRLR,PRAME,PSCA,PSGR,PSMA(FOLH1),RAGE蛋白,Ras,RGS5,Rho,SART-1,SART-3,Steap-1,Steap-2,STn,生存素,TAG-72,TGF-β,TMPRSS2,Tn,TNFRSF17,TRP-1,TRP-2,酪氨酸酶,uroplakin-3,以及以上列出的任一多肽的片段。
配体还可包括锚蛋白重复蛋白、干扰素、淋巴因子(诸如IL-2或IL-3)、激素(如胰岛素和糖皮质激素)、生长因子(诸如EGF)、转铁蛋白,纤连蛋白III型等。
对于治疗用途,本发明的实施方案是靶特异性的。在一个实施方案中,将制备配体,以使其与界定为肿瘤抗原的抗原相互作用并且相结合,所述肿瘤抗原包括特异于肿瘤类型的抗原或在特定类型的肿瘤上共享、过表达或修饰的抗原。所述肿瘤抗原的例子包括:α-辅肌动蛋白-4同肺癌、ARTC1同黑色素瘤、BCR-ABL融合蛋白与慢性粒细胞白血病、B-RAF、CLPP或Cdc27同黑色素瘤、CASP-8同鳞状细胞癌、hsp70-2同肾细胞癌以及以下共享的肿瘤特异性抗原,例如:BAGE-1、GAGE、GnTV、KK-LC-1、MAGE-A2、NA88-A、TRP2-INT2。
生物活性分子
本文的生物活性分子包括在哺乳动物中有治疗用途的任意分子。在典型的实施方案中,所述分子有利地递送至哺乳动物体内的靶标,并且与释放至血管或淋巴系统内的分子相比,其被特别有利地递送,然后至细胞内(例如,内吞作用)。
在某一方面,生物活性分子是引起抑制、延迟、减少和/或阻止细胞生长的化合物。生物活性分子也可通过细胞坏死或凋亡导致细胞死亡。本文描述的用于偶联化合物的示例性生物活性分子包括:美登木素生物碱(例如,DM1、DM4等)、奥利斯他汀类(例如,MMAE、MMAD、MMAF等)、倍癌霉素(duocarmycin)(例如,MGBA)、多拉司他汀(dolastatin)、类毒素和其它化学治疗有效的药物。
可用于本发明上下文的生物活性分子的其它具体例子包括,例如,1-去氢睾酮、2-吡咯啉基多柔比星(2-pyrrolinodoxorubicin)、5-氟尿嘧啶、6-巯基嘌呤、6-硫代鸟嘌呤、放线菌素D、蒽环霉素、氨茴霉素(AMC)、博来霉素、白消安、刺孢霉素、卡莫司汀顺铂、秋水仙碱、氰基吗啉基阿霉素(cyanomorpholino-doxorubicin)、环磷酰胺、阿糖胞苷、细胞松弛素B、更生霉素、道诺霉素、达卡巴嗪(dacarbazine)、二溴甘露醇、二羟基炭疽菌素二酮、阿霉素、依米丁、表阿霉素、溴化乙锭、依托泊苷、短杆菌肽D、糖皮质激素、利多卡因、洛莫司汀(CCNU)、氮芥、美法仑、甲氨蝶呤、光神霉素、丝裂霉素、米托蒽醌、吗啉基阿霉素、普鲁卡因、普萘洛尔、嘌呤霉素、吡咯并苯并二氮杂卓类(pyrrolobenzodiazapines)、西伯利亚霉素、链脲菌素、紫杉醇、替尼泊苷(teniposide)、丁卡因、苯丁酸氮芥(thioepa chlorambucil)、单端孢菌烯(trichothecenes)、单端孢霉烯毒素、tubulysin、长春新碱,以及上述任一种的立体异构体、等排体、类似物或衍生物。
在一个实施方案中,所述生物活性的分子是美登木素生物碱或美登木素生物碱类似物。本文使用的示例性美登木素生物碱是在Widdison等人,J.Med.Chem.,2006,49,4392-4408中所描述的,出于本文全部目的,其通过引用并入本文。
连接体材料
本发明包括连接体化合物,其化学上能够共价连接两个间隔的化学部分。所述连接体分隔和连接两个部分,例如,连接体可以连接配体和生物活性分子。在一方面,所述连接体是自降解(self immolative)的,其中连接体连接两个或更多个不同的化学部分并且在酶的存在下释放至少一个所述化学部分。在另一方面,所述连接体可连接于其它化学部分,包括但不限制于,分析试剂,生物分子,靶向剂,可检测的标签,诊断试剂等等。在一个实施方案中,所述连接体连接生物活性分子和配体。在另一个实施方案中,所述连接体连接具有生物活性的大环内酯类和配体。在另一个实施方案中,所述连接体连接具有生物活性的大环内酯类和抗体或其片段。
在一方面,所述连接体可用于共价连接配体与治疗剂和标记物。另一方面,所述连接体提高了所连接的部分的化学和/或系统稳定性。在另一方面,所述连接体减少所连接的基团在体内的毒性。另一方面,所述连接体改善了所连接部分的药代动力学、药效学和/或生物利用度。在一方面,所述连接体以药理学有效的形式在靶细胞/细胞群内或接近其的位点切割和释放生物活性分子。在一方面,所述切割通过酶进行。在一方面,连接体上用于酶切割的可切割基团包括,但不限制于,肽键、酯键和二硫键。在另一方面,所述连接体通过pH改变而被切割。
在一实施方案中,所述连接体化合物由式(VI)表示:
Z2-A-W-X-Y-Z1 (VI)
其中:
Z2和Z1各自独立不存在或是间隔基;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-、-NR4-;
X不存在,或是芳基、杂芳基、环烷基、杂环基,其中芳基、杂芳基、环烷基和杂环基可选地具有取代基;
Y不存在,或是
其中A1、A3、R1和R3各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基。
A4和A5各自独立是-O-、-S-、-NR18-、-CR5R6-;
R17选自由O、S、NR18、CR5R6构成的组;
R18选自由H、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基构成的组,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基可选地具有取代基;
R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基;
p1、p2和p3各自独立是0,或1-100的整数;和
x是0、1或2。
在一方面,本发明提供了具有式(VI)的化合物,其中Z2由以下结构式表示:
-Z2A-Z2B-Z2C-Z2D-,
其中:
Z2A、Z2B、Z2C和Z2D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基或杂环基。
在一方面,本发明提供了具有式(VI)的化合物,其中Z1由以下结构式表示:
-Z1A-Z1B-Z1C-Z1D-,
其中:
Z1A、Z1B、Z1C和Z1D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基或杂环基。
在一方面,本发明提供了具有式(VI)的化合物,其中A是氨基酸,所述氨基酸选自如下氨基酸所构成的组:丙氨酸、天冬氨酸、谷氨酸、苯丙氨酸、甘氨酸、组氨酸、异亮氨酸、赖氨酸、亮氨酸、蛋氨酸、天冬酰胺、脯氨酸、谷氨酰胺、精氨酸、丝氨酸、苏氨酸、缬氨酸、色氨酸、酪氨酸、半胱氨酸和瓜氨酸。
在另一方面,本发明提供了具有式(VI)的化合物,其中A是肽,所述肽选自如下肽所构成的组:缬氨酸-瓜氨酸、瓜氨酸-缬氨酸、赖氨酸-苯丙氨酸、苯丙氨酸-赖氨酸、缬氨酸-天冬酰胺、天冬酰胺-缬氨酸、苏氨酸-天冬酰胺、丝氨酸-天冬酰胺、天冬酰胺-丝氨酸、苯丙氨酸-天冬酰胺、天冬酰胺-苯丙氨酸、亮氨酸-天冬酰胺、天冬酰胺-亮氨酸、异亮氨酸-天冬酰胺、天冬酰胺-异亮氨酸、甘氨酸-天冬酰胺、天冬酰胺-甘氨酸、谷氨酸-天冬酰胺、天冬酰胺-谷氨酸、瓜氨酸-天冬酰胺、天冬酰胺-瓜氨酸、丙氨酸-天冬酰胺、天冬酰胺-丙氨酸。
在一方面,本发明提供了具有式(VI)的化合物,其中X是芳基,所述芳基选自于以下芳基所构成的组:
其中R9、R10、R11和R12各自独立是H,或是烷基、环烷基、芳基、杂芳基、杂环基、卤素、NR13R14、硝基、氰基、-OH、-O-C(=O)-R15、-C(=O)-R15、-C(=O)-O-R15、-C(=O)-NR13R14;和
进一步其中烷基、环烷基、芳基、杂芳基、杂环基可选地具有取代基;
R13和R14各自独立是H或是可选地具有取代基的烷基;并且R15是可选地具有取代基的烷基。
根据某些实施方案,所述连接体、生物活性的分子以及本发明的其它化合物可通过连接在抗体或抗原结合分子内的特定的氨基酸上而与抗体或抗原结合分子相连接。本发明上下文可使用的典型的氨基酸连接物包括,例如,赖氨酸(参见,例如,US 5,208,020;US2010/0129314;Hollander等,Bioconjugate Chem.,2008,19:358-361;WO 2005/089808;US5,714,586;US 2013/0101546;和US 2012/0585592)、半胱氨酸(参见,例如,US 2007/0258987;WO 2013/055993;WO 2013/055990;WO 2013/053873;WO 2013/053872;WO 2011/130598;US 2013/0101546和US 7,750,116)、硒代半胱氨酸(参见,例如,WO 2008/122039;和Hofer等,Proc.Natl.Acad.Sci.,USA,2008,105:12451-12456)、甲酰甘氨酸(参见,例如,Carrico等,Nat.Chem.Biol.,2007,3:321-322;Agarwal等,Proc.Natl.Acad.Sci.,USA,2013,110:46-51,和Rabuka等,Nat.Protocols,2012,10:1052-1067),非天然氨基酸(参见,例如,WO 2013/068874和WO 2012/166559),和酸性氨基酸(参见,例如,WO 2012/05982)。连接体也可以通过连接至碳水化合物而与抗原结合蛋白偶联(参见,例如,US 2008/0305497,和Ryan等,Food&Agriculture Immunol.,2001,13:127-130)和二硫化物连接体(参见,例如,WO 2013/085925,WO 2010/010324,WO 2011/018611,和Shaunak等,Nat.Chem.Biol.,2006,2:312-313)。
根据某些其它的实施方案,所述连接体、生物活性分子(如药物)可通过连接在抗体或抗原结合分子内特定的氨基酸上以形成抗体-药物偶联物(ADC)而与抗体或抗原结合分子相连接。
化合物
在一方面,本发明提供了由以下结构式(I)所表示的生物活性分子和配体偶联物:
其中:
L不存在或是配体;
进一步其中:
当L是配体时,L能够结合细胞或细胞群;
a是从1到10的整数;
Z2和Z1各自独立不存在或是间隔基;
D是生物活性分子;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-、-NR4-;
X不存在,或是芳基、杂芳基、环烷基、杂环基,其中芳基、杂芳基、环烷基和杂环基可选地具有取代基;和
Y不存在,或是
其中A1、A3、R1和R3各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基。
A4和A5各自独立是-O-、-S-、-NR18-、-CR5R6-;
R17选自由O、S、NR18、CR5R6构成的组;
R18选自由H、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基构成的组,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基可选地具有取代基;
R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基;
p1、p2和p3各自独立是0,或1-100的整数;和
x是0、1或2。
在另一方面,本发明涉及化合物,其中生物活性分子是细胞毒性的生物活性大环内酯物。
在另一方面,本发明提供了由式(II)表示的作为生物活性大环内酯物的美登木素生物碱:
其中A6、A7、A8和A9各自独立不存在,或是氨基酸、N-烷基氨基酸、包括2-20个氨基酸的肽、烷基、烯基、炔基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-NH-、-C(=S)-S-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4,进一步其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基可选地具有取代基;并且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基。
在其它实施方案中,美登木素生物碱由以下结构式(II)(a)表示:
在一方面,本发明提供了具有式(I)的化合物,其中配体(L)能够结合到特异性靶细胞群。
在另一方面,本发明提供了具有式(I)的化合物,其中配体(L)选自由蛋白质、抗体、抗体片段、核酸、抗原结合支架和碳水化合物组成的组。
在一个实施方案中,公开内容提供了具有式(I)的化合物,其中配体(L)是抗体或其片段。
在一个实施方案中,公开内容提供了具有式(I)的化合物,其中配体(L)是特异性结合肿瘤相关的抗原的抗体或其片段。
在一个实施方案中,公开内容提供了具有式(I)的化合物,其中抗体或其片段包含与Z2共价连接的硫基团。
在一方面,本发明提供了具有式(I)的化合物,其中Z2由下列结构式表示:
-Z2A-Z2B-Z2C-Z2D-,
其中:
Z2A、Z2B、Z2C和Z2D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基或杂环基。
在一个实施方案中,公开内容提供了具有式(I)的化合物,其中抗体或其片段包含与Z2A共价连接的硫基团。
在一方面,本发明提供了具有式(I)的化合物,其中Z1由以下结构式表示:
-Z1A-Z1B-Z1C-Z1D-,
其中:
Z1A、Z1B、Z1C和Z1D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基或杂环基。
在一个实施方案中,公开内容提供了具有式(I)的化合物,其中生物活性分子(D)与Z1共价连接。
在一方面,本发明提供了具有式(I)的化合物,其中A氨基酸,所述氨基酸选自如下氨基酸所构成的组:丙氨酸、天冬氨酸、谷氨酸、苯丙氨酸、甘氨酸、组氨酸、异亮氨酸、赖氨酸、亮氨酸、蛋氨酸、天冬酰胺、脯氨酸、谷氨酰胺、精氨酸、丝氨酸、苏氨酸、缬氨酸、色氨酸、酪氨酸、半胱氨酸和瓜氨酸。
在另一方面,本发明提供了具有式(I)的化合物,其中A是肽,所述肽选自如下所构成的组:缬氨酸-瓜氨酸、瓜氨酸-缬氨酸、赖氨酸-苯丙氨酸、苯丙氨酸-赖氨酸、缬氨酸-天冬酰胺、天冬酰胺-缬氨酸、苏氨酸-天冬酰胺、丝氨酸-天冬酰胺、天冬酰胺-丝氨酸、苯丙氨酸-天冬酰胺、天冬酰胺-苯丙氨酸、亮氨酸-天冬酰胺、天冬酰胺-亮氨酸、异亮氨酸-天冬酰胺、天冬酰胺-异亮氨酸、甘氨酸-天冬酰胺、天冬酰胺-甘氨酸、谷氨酸-天冬酰胺、天冬酰胺-谷氨酸、瓜氨酸-天冬酰胺、天冬酰胺-瓜氨酸、丙氨酸-天冬酰胺、天冬酰胺-丙氨酸。
在另一方面,本发明提供了具有式(I)的化合物,其中X是芳基,所述芳基选自于以下所构成的组:
其中R9、R10、R11和R12各自独立是H、烷基、环烷基、芳基、杂芳基、杂环基、卤素、NR13R14、硝基、氰基、-OH、-O-C(=O)-R15、-C(=O)-R15、-C(=O)-O-R15、-C(=O)-NR13R14;和
进一步其中烷基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
R13和R14各自独立是H或是可选地具有取代基的烷基;并且R15是可选地具有取代基的烷基。
在另一方面,本发明提供了具有式(III)的化合物:
其中:
Ab是抗体或其片段;
AA1-AA2是肽,所述肽选自以下所构成的组的肽:缬氨酸-瓜氨酸、瓜氨酸-缬氨酸、赖氨酸-苯丙氨酸、苯丙氨酸-赖氨酸、缬氨酸-天冬酰胺、天冬酰胺-缬氨酸、苏氨酸-天冬酰胺、丝氨酸-天冬酰胺、天冬酰胺-丝氨酸、苯丙氨酸-天冬酰胺、天冬酰胺-苯丙氨酸、亮氨酸-天冬酰胺、天冬酰胺-亮氨酸、异亮氨酸-天冬酰胺、天冬酰胺-异亮氨酸、甘氨酸-天冬酰胺、天冬酰胺-甘氨酸、谷氨酸-天冬酰胺、天冬酰胺-谷氨酸、瓜氨酸-天冬酰胺、天冬酰胺-瓜氨酸、丙氨酸-天冬酰胺、天冬酰胺-丙氨酸;
a是1-10的整数;
q是0或是1-5的整数;
A3、R1和R3各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
R17选自由O、S、NR18、CR5R6构成的组;
R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的烷基、烯基、炔基、芳基、杂芳基和杂环基;
R9、R10、R11和R12各自独立是H、卤素、NR13R14、硝基、氰基、-OH、-O-C(=O)-R15、-C(=O)-R15、-C(=O)-O-R15、-C(=O)-NR13R14、具有取代基或不具有取代基的:烷基、环烷基、芳基、杂芳基和杂环基;
R13和R14各自独立是H或是可选地具有取代基的烷基;并且R15是可选地具有取代基的烷基;
p1、p2和p3各自独立是0或是1-100的整数;
x是0、1或2;且DM由如下结构所表示(例如:具有式(II)(a)的化合物):
在一个实施方案中,公开内容提供了具有式(III)的化合物:
其中:
q是4;
R1和R3各自独立地是-O-、-S-、-NR4-、-CR5R6-;
R17选自由O、S、NR18、CR5R6构成的组;
R18选自由H、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基构成的组,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基可选地具有取代基;
R4、R5、R6、R9、R10、R11、R12各自独立是H或烷基;和
A3是烷基。
在一个实施方案中,公开内容提供了由如下结构式(III)(a)和(III)(b)表示的具有式(III)的化合物:
其中Ab是抗体或其片段。
在一方面,本发明提供了具有式(IV)的化合物:
其中:
Ab是抗体或其片段;
AA1-AA2是选自以下所构成的组的肽:缬氨酸-瓜氨酸、瓜氨酸-缬氨酸、赖氨酸-苯丙氨酸、苯丙氨酸-赖氨酸、缬氨酸-天冬酰胺、天冬酰胺-缬氨酸、苏氨酸-天冬酰胺、丝氨酸-天冬酰胺、天冬酰胺-丝氨酸、苯丙氨酸-天冬酰胺、天冬酰胺-苯丙氨酸、亮氨酸-天冬酰胺、天冬酰胺-亮氨酸、异亮氨酸-天冬酰胺、天冬酰胺-异亮氨酸、甘氨酸-天冬酰胺、天冬酰胺-甘氨酸、谷氨酸-天冬酰胺、天冬酰胺-谷氨酸、瓜氨酸-天冬酰胺、天冬酰胺-瓜氨酸、丙氨酸-天冬酰胺、天冬酰胺-丙氨酸;
a是1-10的整数;
q是0或是1-5的整数;
R1不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
R4是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基和杂环基;
R9、R10、R11和R12各自独立是H、卤素、NR13R14、硝基、氰基、-OH、-O-C(=O)-R15、-C(=O)-R15、-C(=O)-O-R15、-C(=O)-NR13R14,具有取代基或不具有取代基的烷基、环烷基、芳基、杂芳基、杂环基;和
DM由如下结构所表示:
在一个实施方案中,公开内容提供了具有式(IV)的化合物:
其中:
q是4;和
R1选自由-O-、-S-、-NR4-、和-CR5R6-构成的组;和
进一步其中R4、R5和R6各自独立是H或烷基。
在一个实施方案中,公开内容提供了由如下结构(IV)(a)表示的具有式(IV)的化合物:
其中Ab是抗体或其片段。
在一方面,本发明提供了具有式(V)的化合物:
Z2-A-W-X-Y-Z1-D (V)
其中:
Z2和Z1各自独立不存在或是间隔基;
D是生物活性分子;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-或-NR4-;
X不存在,或是具有取代基或不具有取代基的:芳基、杂芳基、环烷基、杂环基;
Y不存在,或是
其中A1、A3、R1和R3各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基。
A4和A5各自独立是-O-、-S-、-NR18-、-CR5R6-;
R17选自由O、S、NR18、CR5R6构成的组;
R18选自由H、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基构成的组,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基可选地具有取代基;
R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、杂环基;
p1、p2和p3各自独立是0,或1-100的整数;和
x是0、1或2。
在一个实施方案中,公开内容提供了具有式(V)的化合物,
其中:
Z2由式(VII)表示:
-Z2A-Z2B-Z2C-Z2D- (VII),
进一步其中:
Z2A、Z2B、Z2C和Z2D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、杂环基;
Z1由式(VIII)表示:
-Z1A-Z1B-Z1C-Z1D- (VIII),
其中:
Z1A、Z1B、Z1C和Z1D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、杂环基;
A是肽,所述肽选自如下肽所构成的组:缬氨酸-瓜氨酸、瓜氨酸-缬氨酸、赖氨酸-苯丙氨酸、苯丙氨酸-赖氨酸、缬氨酸-天冬酰胺、天冬酰胺-缬氨酸、苏氨酸-天冬酰胺、丝氨酸-天冬酰胺、天冬酰胺-丝氨酸、苯丙氨酸-天冬酰胺、天冬酰胺-苯丙氨酸、亮氨酸-天冬酰胺、天冬酰胺-亮氨酸、异亮氨酸-天冬酰胺、天冬酰胺-异亮氨酸、甘氨酸-天冬酰胺、天冬酰胺-甘氨酸、谷氨酸-天冬酰胺、天冬酰胺-谷氨酸、瓜氨酸-天冬酰胺、天冬酰胺-瓜氨酸、丙氨酸-天冬酰胺、天冬酰胺-丙氨酸;和
X是选自以下所构成的组的芳基:
其中R9、R10、R11和R12各自独立是H、烷基、环烷基、芳基、杂芳基、杂环基、卤素、NR13R14、硝基、氰基、-OH、-O-C(=O)-R15、-C(=O)-R15、-C(=O)-O-R15、-C(=O)-NR13R14;和
进一步其中烷基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
R13和R14各自独立是H或是可选地具有取代基的烷基;并且R15是可选地具有取代基的烷基。
生物活性分子(D)可选择性地是被取代的具有式(II)的美登木素生物碱:
其中:
A6、A7、A8、A9各自独立不存在,或是氨基酸、N-烷基氨基酸、包括2-20个氨基酸的肽、烷基、烯基、炔基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4,进一步其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;并且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、杂环基。
在另一实施方案中,公开内容提供了具有式(V)的化合物,其中所述生物活性分子是由如下结构式表示的可选地具有取代基的美登木素生物碱:
其中:
A6、A7、R8和R9各自独立不存在,或是氨基酸、N-烷基氨基酸、包括2-20个氨基酸的肽、烷基、烯基、炔基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、C(=O)-N(R4)-C(=O)-、O-C(=O)-NR4,进一步其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;并且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、杂环基。
在另一实施方案中,公开内容提供了具有式(V)的化合物,其中所述生物活性分子是由如下结构式表示的美登木素生物碱:
在一个实施方案中,公开内容提供了具有式(V)的化合物,其由如下结构(V)(a)、(V)(b)、(V)(c)、(V)(d)和(V)(e)表示:
在一方面,本发明提供了具有式(IX)的化合物:
Y1-Z1-D (IX)
D是生物活性分子;
其中R3a和A3a各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;和
Z1由以下结构式表示:
-Z1A-Z1B-Z1C-Z1D-,
其中:
Z1A、Z1B、Z1C和Z1D各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1、-C(=O)-O-(CHx)p1、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、C(=O)-N(R4)-C(=O)-、-O-C(=O)-N(R4)、-O-C(=S)-N(R4)-、-C(=S)-N(R4)-、-N=C=S、-N=C=O、
其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基,且R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基或杂环基。
在另一方面,本发明提供了具有式(IX)的化合物,其中所述的生物活性分子是细胞毒性的生物活性大环内酯物。另一方面,本发明提供了具有式(IX)的化合物,其中所述的生物活性大环内酯物是美登木素生物碱。在更进一步的方面,本发明提供了具有式(IX)的化合物,其中所述的美登木素生物碱由式(II)表示。另一方面,本发明提供了具有式(IX)的化合物,其中所述的美登木素生物碱由式(II)(a)表示。
在一方面,本发明提供了具有式(IX)的化合物,其中所述化合物的IC50大于约10nM。
在一方面,本发明提供了具有式(IX)的化合物,其中所述化合物的细胞毒性比具有式(I)的相应化合物的细胞毒性低大约10倍。
在另一方面,本发明提供了具有式(X)的化合物:
其中:
Ab是抗体或其片段;
a是从1到10的整数;
Z2和Z1各自独立不存在或是间隔基;
A是天然或非天然氨基酸、或包括2-20个氨基酸的肽;
W不存在,或是-O-、-S-、-CR5R6-、-NR4-;
X不存在,或是芳基、杂芳基、环烷基、杂环基,其中芳基、杂芳基、环烷基和杂环基可选地具有取代基;和
Y不存在,或是
其中A1、A3、R1和R3各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-S-C(=S)-、-C(=S)-NH-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
A4和A5各自独立是-O-、-S-、-NR18-、-CR5R6-;
R17选自由O、S、NR18、CR5R6构成的组;
R18选自由H、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基构成的组,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基和酰基可选地具有取代基;
R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基、或杂环基;
p1、p2和p3各自独立是0,或1-100的整数;
x是0、1或2;和
DM由以下结构所表示:
在一个实施方案中,公开内容提供了由如下结构(X)(a)表示的具有式(X)的化合物:
其中a是1-10的整数。
在另一方面,本发明提供了具有式(XI)的化合物:
其中:
Ab是抗体或其片段;
AA1-AA2是选自以下所构成的组的肽:缬氨酸-瓜氨酸、瓜氨酸-缬氨酸、赖氨酸-苯丙氨酸、苯丙氨酸-赖氨酸、缬氨酸-天冬酰胺、天冬酰胺-缬氨酸、苏氨酸-天冬酰胺、丝氨酸-天冬酰胺、天冬酰胺-丝氨酸、苯丙氨酸-天冬酰胺、天冬酰胺-苯丙氨酸、亮氨酸-天冬酰胺、天冬酰胺-亮氨酸、异亮氨酸-天冬酰胺、天冬酰胺-异亮氨酸、甘氨酸-天冬酰胺、天冬酰胺-甘氨酸、谷氨酸-天冬酰胺、天冬酰胺-谷氨酸、瓜氨酸-天冬酰胺、天冬酰胺-瓜氨酸、丙氨酸-天冬酰胺、天冬酰胺-丙氨酸;
a是1-10的整数;
q是0或是1-5的整数;
A3、R1和R3各自独立不存在,或是氨基酸、包括2-20个氨基酸的肽、烷基、炔基、烯基、环烷基、芳基、杂芳基、杂环基、-CR5R6-、-O-、-C(=O)-、-O-C(=O)-、-C(=O)-O-、-O-C(=O)-O-、-C(=O)-(CHx)p1-、-C(=O)-O-(CHx)p1-、-(CHx)p1-C(=O)-、-(CHx)p1-C(=O)-O-、-(O-(CH2)p2-)p3-、-((CH2)p2-O-)p3-、-C(=S)-、-C(=S)-S-、-C(=S)-NH-、-S-C(=S)-、-S-C(=S)-S-、-S-、-SO-、-SO2-、-NR4-、-N(R4)-C(=O)-N(R8)-、-N(R4)-C(=O)O-、-N(R4)-C(=O)-、-C(=O)-N(R4)-、-C(=O)-N(R4)-C(=O)-、-O-C(=O)-NR4-,其中烷基、炔基、烯基、环烷基、芳基、杂芳基、和杂环基可选地具有取代基;
R17选自由O、S、NR18、CR5R6构成的组;
R4、R5、R6和R8各自独立是H,或是具有取代基或不具有取代基的:烷基、烯基、炔基、芳基、杂芳基和杂环基;
R9、R10、R11和R12各自独立是H、卤素、NR13R14、硝基、氰基、-OH、-O-C(=O)-R15、-C(=O)-R15、-C(=O)-O-R15、-C(=O)-NR13R14,具有取代基或不具有取代基的烷基、环烷基、芳基、杂芳基、和杂环基;
R13和R14各自独立是H或是可选地具有取代基的烷基;并且R15是可选地具有取代基的烷基;
p1、p2和p3各自独立是0或是1-100的整数;
x是0、1或2;和
DM由如下结构所表示:
在一个实施方案中,公开内容提供了由如下结构(XI)(a)表示的具有式(XI)的化合物:
其中a是1-10的整数。
在一方面,本发明提供了具有式(I)、(III)、(IV)、(V)和(X)化合物,其中A是由蛋白酶可切割的肽。
在一方面,本发明提供了具有式(XI)的化合物,其中的肽是由蛋白酶可切割的。
在一方面,本发明提供了具有式(I)、(III)、(IV)、(V)和(X)的化合物,其中A是由在肿瘤组织中表达的蛋白酶可切割的肽。
在一方面,本发明提供了具有式(XI)的化合物,其中的所述的肽是由在肿瘤组织中表达的蛋白酶可切割的。
在一个实施方案中,公开内容提供了具有式(I)、(III)、(IV)、(V)、(X)的化合物,其中A是由蛋白酶可切割的肽,进一步其中所述的蛋白酶是组织蛋白酶或纤溶酶。
在一个实施方案中,公开内容提供了具有式(XI)的化合物,其中所述的肽是由蛋白酶可切割的,进一步其中所述的蛋白酶是组织蛋白酶或纤溶酶。
组合物
本文的实施方案包括组合物,所述组合物包括具有式(I)、(III)、(IV)、(V)、(X)或(XI)的偶联化合物以及它们的混合物。在某些方面,所述化合物进一步由具有式(III)(a)、(III)(b)、(IV)(a)、(V)(a)、(V)(b)、(V)(c)、(V)(d)、(V)(e)、(X)(a)或(XI)(a)的化合物表示。
本文的实施方案包括组合物,所述组合物包括具有式(I)、(III)、(IV)、(V)、(IX)、(X)或(XI)的化合物以及它们的混合物。
所述组合物可为药物组合物,所述药物组合物进一步包括一种或多种药学上可接受的载体,稀释剂和/或赋形剂。在某些方面,所述药物组合物是具有式(I)、(III)、(IV)、(V)、(IX)、(X)或(XI)的化合物的在药学上可接受的盐或它们的混合物。在其他一些方面,所述的药物组合物是具有式(I)、(III)、(IV)、(V)、(IX)、(X)或(XI)的化合物的在药学上可接受的盐或它们的混合物。
合适的药学上可接受的载体、稀释剂和赋形剂是本领域熟知的,并且可以由本领域普通技术人员根据临床情况需要来确定。合适的载体、稀释剂和赋形剂的例子包括:用于维持适当的组合物pH的缓冲液(例如,柠檬酸盐缓冲液、琥珀酸盐缓冲液、醋酸缓冲液、磷酸盐缓冲液、乳酸盐缓冲液、草酸盐缓冲液等)、载体蛋白(例如,人血清白蛋白)、生理盐水、多元醇(例如,海藻糖、蔗糖、木糖醇、山梨糖醇等)、表面活性剂(例如,聚山梨醇酯20、聚山梨醇酯80、聚乙二酸酯(polyoxolate)等)、抗菌剂和抗氧化剂。
如果需要,本文所述药物组合物可包括第二种或更多的治疗剂(例如,具有式(I)、(III)、(IV)、(X)和/或(XI)的偶联化合物的佐剂、抗肿瘤制剂、抗生素、抗炎药等)。第二治疗剂可包括在与具有式(I)、(III)、(IV)、(V)、(IX)、(X)和/或(XI)的化合物相同的组合物中,或可以与具有式(I)、(III)、(IV)、(V)、(IX)、(X)和/或(XI)的化合物分开施用(通过施用时间、或类型和位置)。
在生物活性分子领域的技术人员会理解可以以产生的化合物仍保留类似于起始化合物的特异性和/或活性的这种方式修改具有式(I)、(III)、(IV)、(V)、(IX)、(X)和/或(XI)的每一个化合物。从这个角度,具有式(I)、(III)、(IV)、(V)、(IX)、(X)和/或(XI)的化合物的生物活性分子(D)可以包括任一和全部的所述生物活性分子的类似物和衍生物。在一个实施方案中,所述生物活性分子是大环内酯物并且进一步是美登素或美登素,其在Widdison等人,J.Med.Chem.,2006,49(14),4392-4408中有描述。
在一方面,本发明提供药物组合物,所述药物组合物包括治疗有效量的具有式(I)、(III)、(IV)、(X)、(XI)(包括(III)(a)、(III)(b)、(IV)(a)、(X)(a)和(XI)(a))的化合物,或其药学上可接受的盐和一种或多种药学上可接受的载体、稀释剂或赋形剂。
在一个方面,本发明提供药物组合物,所述药物组合物包括治疗有效量的具有式(I)、(III)、(IV)、(V)、(IX)、(X)、(XI)(包括(III)(a)、(III)(b)、(IV)(a)、(V)(a)、(V)(b)、(V)(c)、(V)(d)和(V)(e)、(X)(a)和(XI)(a))的化合物,或其药学上可接受的盐和一种或多种药学上可接受的载体、稀释剂或赋形剂。
另一方面,本发明提供药物组合物,所述药物组合物包括治疗有效量的具有式(V)(包括(V)(a)、(V)(b)、(V)(c)、(V)(d)和(V)(e))的化合物,或其药学上可接受的盐和一种或多种药学上可接受的载体、稀释剂或赋形剂。
另一方面,本发明提供药物组合物,所述药物组合物包括治疗有效量的具有式(IX)的化合物、或其药学上可接受的盐和一种或多种药学上可接受的载体、稀释剂或赋形剂。
在另一方面,本发明提供药物组合物,所述药物组合物包括治疗有效量的具有式(V)和(IX)(包括(V)(a)、(V)(b)、(V)(c)、(V)(d)和(V)(e))的化合物,或其药学上可接受的盐和一种或多种药学上可接受的载体、稀释剂或赋形剂。
使用方法
如上所述,利用各种官能团可产生具有式(I)、(III)、(IV)、(X)、(XI)的偶联化合物,所述官能团使得配体(L)与连接体连接,从而使生物活性分子形成共价偶联物。所述配体特异性地将偶联化合物靶向配体结合伴侣,所述结合伴侣通常是多肽或其它类似的抗原。在典型的实施方案中,所述偶联物被设计为包括具有结合伴侣的配体,所述结合伴侣在发生异常细胞生长或涉及增殖性病症的细胞上发现。令人惊讶的是,具有式(I)、(III)、(IV)、(X)和(XI)的偶联化合物被设计为,在结合该偶联物的细胞内使得每个化合物的连接体分解代谢。同样地,通过本文偶联物的实施方案进行的生物活性分子的递送允许递送通常毒性太强而不能常规施用的生物活性分子。本文的实施方案允许高度选择性和特异性递送这些分子至发生异常细胞生长或涉及增殖性病症(例如,相比于细胞外的分解代谢,从而释放生物活性化合物至血液或淋巴系统内)的细胞。
如本领域技术人员可预期的,本文所描述的共价偶联物化合物也可用于递送任何类型的有益的生物活性分子,并且可以选择性地靶向任何类型的细胞群,例如,只要选定的配体识别适当的细胞结合伴侣,所述偶联物可以用于将抗增殖药物传递至发生异常生长的细胞或将抗病毒药物传递至受病毒感染的细胞。
从这个角度,针对本文所描述的偶联物化合物的实施方案提供使用方法。
本发明所描述的药物组合物在哺乳动物体内可用于抑制、延缓和/或防止异常细胞生长或治疗各种增殖性病症或疾病状态。在典型的实施方案中,所述哺乳动物是人类(本文将描述关于人类的实施方案)。其他哺乳动物包括患有可检测的增殖性病症的任何哺乳动物,包括灵长类动物、狗、猫、马、山羊、绵羊、牛、骆驼等。此外,据了解,所述药物组合物的偶联物化合物被设计用于选择性靶向发生异常细胞生长的细胞或用于治疗本文描述的各种增殖性病症或疾病状态。
同样地,本文的实施方案包括在人体内抑制异常细胞生长或治疗增殖性病症的方法,所述方法包括将治疗有效量的本文描述的药物组合物施用至人体。
施用治疗有效量的本文所描述的药物组合物可能会受到不同方式的影响,如,通过静脉内、腹腔内、皮下、肌内、局部、皮内、鼻内或支气管内施用。本文所述的药物组合物还可以直接施用至异常细胞生长的位点(直接或间接接触异常细胞生长),其通过例如,基因枪递送(biolistic delivery)(例如,基因枪递送本文所述的药物组合物至肺或脑肿瘤)。用于施用的本文所述的药物组合物的剂量量(dosage regiments)由本领域主治的卫生保健的专业人员或其他人员基于特定的临床表现来决定。正如药物领域众所周知的,对任何一个人(即病人)的剂量,取决于许多因素,包括患者的大小、患者的体表面积、患者的年龄和综合健康状况、患者的性别、施用的时间和途径、第二治疗剂的存在。在某些情况下,具有式(I)、(III)、(IV)、(X)和/或(XI)的偶联物化合物可以1μg-100mg/kg体重每剂量的量存在(注意,当持续静脉滴注被考虑作为给药途径时,可以考虑低至1pg/kg体重每分钟)。药物组合物可一天施用一次或多次,并在几天、几周、几个月或几年内施用。
治疗增殖性病症或疾病(例如,肿瘤),包括减少肿瘤尺寸、导致肿瘤坏死或凋亡、杀死肿瘤、停止肿瘤尺寸增加和/或阻止肿瘤侵入或转移的方法。
可根据抑制异常细胞生长、或治疗增生性病症的方法来治疗的医学病症的例子包括:任何类型的恶性肿瘤,如肺癌、结肠癌、前列腺癌、肾癌、胰腺癌、肝癌、卵巢癌、皮肤癌、淋巴癌、白血病等;自身免疫性疾病,如系统性红斑狼疮、类风湿性关节炎、多发性硬化症;病毒感染,如CMV感染、HIV感染、AIDS、肝炎、HPV感染;疼痛;精神障碍和炎症性疾病等。
如上所述,本文所描述的药物组合物在预防或治疗哺乳动物体内病毒感染、疼痛、炎症性疾病、自身免疫性疾病方面也同样有用。
在一方面,本发明提供了减少、延缓或阻止异常细胞生长的方法,所述方法包括使异常细胞与具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物接触,所述化合物具有足以延缓、减少或阻止异常细胞生长的量,并使其中所述的异常细胞生长被延缓、减少或停止。
在一方面,本发明提供了杀死细胞的方法,所述方法包括使细胞与具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物接触,所述化合物具有足以杀死细胞的量,并且其中所述的细胞被杀死。
在一个实施方案中,公开内容提供了杀死细胞的方法,所述方法包括将细胞与具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物接触,所述化合物具有足以杀死细胞的量,并且其中所述的细胞被杀死且进一步其中所述的细胞是肿瘤细胞。
在一方面,本发明提供了治疗患有医学病症的个体的医学病症的方法,所述方法包括将有效量的组合物施用至个体,所述组合物包括具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物。
在另一方面,本发明提供了治疗患有医学病症的个体的医学病症的方法,所述方法包括将有效量的组合物施用至个体,所述组合物包括具有式(I)、(III)、(IV)、(V)、(IX)、(X)和/或(XI)的化合物。
在一个实施方案中,公开内容提供了治疗患有医学病症的个体的医学病症的方法,所述方法包括将有效量的组合物施用至个体,并且进一步包括顺序地施用或连续地施用额外的治疗,所述组合物包括具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物。
在一个实施方案中,公开内容提供的方法,其中额外的治疗是放射治疗、化疗或两者的组合。
在一个实施方案中,公开内容提供了治疗患有医学病症的个体的医学病症的方法,所述方法包括将有效量的组合物施用至个体,并且进一步包括顺序地施用或连续地施用额外的治疗以及施用至少一种额外的治疗剂,所述组合物包括具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物。
在一个实施方案中,公开内容提供了治疗患有医学病症的个体的医学病症的方法,所述方法包括将有效量的组合物施用至个体,并且进一步包括顺序地施用或连续地施用额外的治疗或施用至少一种额外的治疗剂,所述组合物包括具有式(I)、(III)、(IV)、(X)和/或(XI)的化合物。
在一方面,被治疗的医学病症选自肿瘤、癌症、传染性疾病、神经退行性疾病、骨骼疾病和心血管疾病。
本文的实施方案还提供了由式(V)的前体或结构单元(building blockcompound)化合物制备具有式(I)的化合物的方法。在某些方面,当具有式(V)的化合物是药物组合物时,所述具有式(V)的化合物也可用于治疗性应用。在某些方面,具有式(V)的化合物可包含于化合物(I)、(III)、(IV)、(IX)、(X)和/或(XI)的任一组合物或药物组合物中。
最后,文本的实施方案可包括由式(I)、(III)、(IV)、(V)、(IX)、(X)和/或(XI)表示的化合物的混合物。
偶联物的产生
配体-生物活性分子偶联物化合物可通过技术人员已知的任何技术生产。所述配体-生物活性分子偶联物化合物包括配体单元、生物活性分子和任选地连接生物活性分子和配体的连接体。生物活性分子和/或连接体与配体的共价连接可通过使用配体(例如,抗体)的氨基酸残基、利用各种反应来完成,所述配体的氨基酸残基包括赖氨酸的氨基、谷氨酸和天冬氨酸的游离的羧酸基团,半胱氨酸的巯基和芳香族氨基酸的各种部分。
进一步,依照本文所描述的各种实施方案的偶联物,可由本领域任何已知的方法来制备。在下面的例子中提供了用于生产偶联物的说明性方案。然而,可使用其它已知的方法,包括例如,在WO 2009/134977,美国专利号7,811,572和美国专利号6,441,163中所描述的方案,只要是用于制备本文所描述的化合物的方案。出于它们的预期目的,这些参考文献通过引用并入本文。
在一个实施方案中,所述偶联物可通过如下方法制备:i)将配体与连接体反应以形成经修饰的配体-连接体化合物;ii)选择性地纯化所述配体-连接体化合物;iii)使生物活性分子(例如,大环内酯物)与配体-连接体偶联,以形成具有式(I)、(III)、(IV)、(X)或(XI)的偶联物;和iv)纯化所述偶联物。
在另一个供选择的实施方案中,所述偶联物可以通过如下方法制备:使生物活性分子与连接体(Z1)的第一组成部分(component)反应,然后通过连续反应来增建连接体,包括添加Y、X、W、A和Z2,或它们的任意组合。
在一个供选择的实施方案中,所述偶联物可以通过如下方法制备:使配体、连接体和生物活性大环内酯物在单一反应里进行反应。一旦制备出依照本发明的偶联物,它们就可以被纯化。
确定偶联化合物的细胞毒性
在一个实施方案中,可以评价本文所描述的偶联化合物在体外抑制各种癌细胞系增殖的能力。体外细胞毒性试验可以使用本领域已知的方法(参见Widdison等人,J.Med.Chem.,2006,49(14),4392-408)和本文实施例7所阐述的方法进行。例如,可将偶联化合物应用于体外板上的癌细胞(plated cancer cell)达预先确定的天数,并在试验中通过已知的方法测量存活的细胞。可利用适当的对照以确保试验结果(IC50值)的有效性。本文偶联化合物的体外效力的例子可参见图1和图2。额外的体内功效可用于确认提出的偶联化合物的效力,例如使用裸小鼠模型。
上述说明书、实例和数据对本发明组合物的生产和使用提供了完整的描述。由于本发明的许多实施方案在不背离本发明的精神和范围下做出,所以本发明归属于本文所附的权利要求。
本文所引用的和随后例子中的所有参考文献,以其整体通过引用清楚地并入本文。
下文提供的描述和例子用于说明本发明。本领域技术人员将认识到这些例子仅通过举例说明的方式来提供,而并不是为了限制本发明的目的而被包括。
实施例
实验细节
质子NMR谱(对不能通过UV检测的化合物)在Varian Inova 300MHz仪器上获得,而质谱在具有电喷雾电离源和三重四极离子阱分析器的Agilent 1100系列LC/MSD上收集。适当的偶联物使用BrukerultraFleXtreme MALDI-TOF-TOF质谱仪分析。所有起始材料和溶剂均为商业可购买的并且未经过纯化使用,除非另有说明。
实施例
步骤1:美登素(Maytansin)-3-N-甲基-L-丙氨酸(2)
通过使用美国专利申请2007/0037972A1中所描述的方法由美登醇(1)制备出标题的金色固体化合物。MS(ESI,pos.):C32H44ClN3O9的计算值,649.3;实测值650.6(M+H)。
步骤2:美登素-3-N-甲基-L-(S)-丙氨酸-N-[4-(氨基-瓜氨酸-缬氨酸-己酰胺-6-马来酰亚胺基)苄基]氨基甲酸酯(3):
在一锥形小瓶内,将之前步骤的产物(2,0.020g,0.031mmol)和p-NO2-Ph-碳酸(carbonato)-Bn-Cit-Val-马来酰亚胺(MA-VC-PAB-PNP,0.027g,0.037mmol;ConcortisBiosystems)溶解于N,N-二甲基甲酰胺(DMF,约0.25mL)中,经过Brockmann I碱性氧化铝(0.10g)处理,所述小瓶经氩气吹扫,并且在室温下搅拌反应4天。然后将混合物进行过滤,得到的固体经过乙腈/水洗涤,且滤液直接在5u,30x150mm Phenomenex Gemini C18柱上经HPLC(30-90%乙腈水溶液,在乙腈和水中的0.1%TFA,经25min,15mL/min)纯化。将最纯的级分过夜冻干,获得为淡黄色固体的标题化合物(0.021g,55%)。MS(ESI,pos.):C61H82ClN9O17计算值1247.6;实测值1248.8(M+H),1270.7(M+Na),1231.5(M-H2O+H)。
alumina:氧化铝
实施例2
步骤1:N-叔丁基-丁氧基羰基-β-丙氨酸琥珀酸酯(4)
通过本领域熟知的方法由商用Boc-β-丙氨酸制备出标题化合物(c.f.-Widdison等,J.Med.Chem.,2006,49(14),4401)。1H NMR(300MHz,CDCl3):δ3.62(bm,2H),2.88(m,9H),1.47(s,9H)。
步骤2:美登素-3-N-甲基-L-(S)-丙氨酸-Boc-β-Ala(5)
将之前步骤的产物(4,0.45g,1.51mmol)和美登素-3-N-甲基-L-丙氨酸(2,0.30g,0.23mmol)溶解于3:1乙腈:水(8mL)中,经过1M NaHCO3水溶液处理(0.5mL),并且在室温下搅拌18h。当通过TLC监测反应完全,然后同盐水搅拌10min并经乙酸乙酯(EtOAc)萃取3次。然后合并的有机层经Na2SO4干燥,过滤,滤液在真空中浓缩和干燥至金色浆状物,在20g硅胶柱(0-10%MeOH的EtOAc溶液,经15min)上经快速柱层析纯化,得到为白色固体的标题化合物(0.084g,43%)。MS(ESI,pos.):C41H59ClN4O12计算值,834.4;实测值835.2(M+H),857.2(M+Na),817.4(M-H2O+H)。
步骤3:美登素-3-N-甲基-L-(S)-丙氨酸-β-Ala(6)
将之前步骤的产物(5,0.080g,0.095mmol)溶解于3:1:1的乙腈/水/三氟乙酸混合物(4mL)中,并且在室温下搅拌26小时。将粗反应混合物直接注入40g C18硅胶柱上并通过ISC℃ombiFlash(10-90%乙腈水溶液,在各溶剂中的0.1%TFA,经18min,40mL/min)洗脱,并将合并的纯化级分冻干,获得为淡黄色固体的标题化合物(0.025g,31%)。MS(ESI,pos.):C36H51ClN4O10计算值,734.3;实测值735.5(M+H)。
步骤4:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺基-3-N-甲基-N-[4-(氨基-瓜氨酸-缬氨酸-己酰胺-6-马来酰亚胺基)苄基]氨基甲酸酯(7)
将之前步骤的产物(6,0.014g,0.019mmol)和MA-VC-PAB-PNP(0.020g,0.027mmol;Concortis Biosystems)溶解于4:1乙腈/水(2.5mL)中,经过0.1M NaHCO3水溶液(0.5mL)处理,并且在室温下搅拌18h。所述反应直接在C18硅胶(使用0.1%TFA的乙腈/水梯度溶液)上通过反相层析纯化。最终的柱级分经过冻干后获得为白色固体的标题化合物(0.002g,8%)。MS(ESI,pos.):C65H89ClN10O18计算值,1332.6;实测值1333.9(M+H),1316.5(M-H2O+H),1355.9(M+Na)。
Maytan:美登素
实施例3
Step 1:3-甲基二硫代-丙酸琥珀酸酯(8)
通过使用Widdison等.J.Med.Chem.,2006,49(14),4392-4408中所描述的方法由3-巯基丙酸制备出为白色固体的标题化合物。1H NMR(300MHz,CDCl3)δ3.09(m,2H),3.01(m,2H),2.86(s,4H),2.44(s,3H)。
Step 2:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺基-3-甲基二硫化物(9)
将之前步骤的产物(8,2.96g,11.9mmol)和美登素-3-N-甲基-L-丙氨酸(2,1.54g,2.37mmol)溶解于4:1乙腈/水(25mL)中,经过饱和NaHCO3水溶液(2mL)处理,并且在室温下搅拌24小时。所述反应混合物经过盐水处理,经EtOAc萃取3次,水层通过NaCl饱和,再次经EtOAc萃取,将合并的有机层经过Na2SO4干燥,过滤。滤液在真空下浓缩至金色浆状物(约4.5g),在80g硅胶柱(0-10%EtOAc的己烷溶液,经30min)上经快速柱层析纯化,获得为白色固体的标题化合物(1.14g,61%)。MS(ESI,pos.):C36H50ClN3O10S2计算值,783.3;实测值784.3(M+H),766.6(M-H2O+H)。
步骤3:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺-3-硫醇(10)
通过使用Whitesides等(J.Org.Chem.,1991,56,2648-2650)中所描述的方法的改良版制备出标题化合物。将之前步骤的产物(9,2.42g,3.09mmol)溶解于乙腈(30mL)中,经过在30mL水中的三(2-羧乙基)膦盐酸盐(8.23g,28.7mmol)溶液处理,添加NaHCO3饱和水溶液(5mL)后pH升至3,烧瓶经Ar吹扫,并且在橡胶隔片(由于泡腾(effervescence)而是通气的(vented))下室温搅拌反应。2小时后,反应经过盐水(约100mL)处理,以Ar鼓泡5min(以除去游离的甲硫醇),并且分相。水相经过EtOAc萃取2次,经NaCl饱和,然后再经过EtOAc萃取2次。然后将合并的有机层经Na2SO4干燥,过滤,且滤液在真空下浓缩和干燥,获得为白色固体的标题化合物(2.24g,98%)。MS(ESI,pos.):C35H48ClN3O10S计算值,737.3;实测值738.3(M+H),720.3(M-H2O+H)。
步骤4:4-氨基-(N-苄氧基羰基)苄胺(14)
在N2环境下,将4-氨基苄胺(1.00g,8.18mmol)和三乙胺(1.20mL,8.61mmol)溶解于无水四氢呋喃(THF,10mL)中,在盐水/冰浴中搅拌冷却,然后经氯甲酸苄酯(1.20mL,8.41mmol)的无水THF(10mL)溶液逐滴处理20min。添加完成后,去除冰浴并在室温下搅拌反应20小时,然后经过烧结玻璃漏斗过滤以去除不溶物。将固体经过EtOAc洗涤,滤液在真空下浓缩,且浓缩剩余物在40g硅胶柱(0-10%EtOAc的己烷溶液,经20min,40mL/min)上经快速柱层析纯化。在真空下蒸干纯化的中间-流动(mid-running)级分而获得为浅黄色固体的标题化合物(1.47g,70%)。MS(ESI,pos.):C15H16N2O2计算值,256.1;实测值256.9(M+H),278.9(M+Na)。
步骤5:6-马来酰亚胺基己酸琥珀酸酯(20)
通过使用与Marnett等(J.Med.Chem.,1996,39,1692-1703)中所描述的相似的方法,由商用6-氨基己酸制备出标题的无色胶状化合物。1H NMR(300MHz,CDCl3)δ6.72(s,2H),3.56(t,2H,J=7Hz),2.86(s,4H),2.64(t,2H,J=7Hz),1.81(五重峰,2H,J=8Hz),1.66(m,2H),1.45(m,2H)。
步骤6:Boc-缬氨酸-琥珀酸酯(11)
通过本领域熟知的方法(Widdison等,J.Med.Chem.,2006,49(14),4401)由Boc-Val-OH制备出标题的白色固体化合物。1H NMR(300MHz,CDCl3)δ5.03(d,1H,J=10Hz),4.60(dd,1H,J=9Hz,5Hz),2.85(s,4H),2.32(m,1H),1.47(s,9H),1.05(m,6H)。
步骤7:Boc-缬氨酸-瓜氨酸(12)
将之前步骤的产物(11,4.23g,13.5mmol)溶解于乙腈(70mL)中,经过L-瓜氨酸(3.20g,18.3mmol)的水(30mL)溶液和饱和NaHCO3溶液(18mL)处理,烧瓶经N2吹扫,然后在室温下搅拌反应24小时。混合物在真空下浓缩以去除乙腈,经EtOAc洗涤一次以去除非极性杂质,将水层用NaCl饱和并用10%HCl酸化至pH=3。产生的浑浊混合物经过10%异丙醇的EtOAc溶液萃取4次,将合并的有机层经Na2SO4干燥,过滤。在真空下浓缩后干燥滤液,获得为白色固体的标题化合物(4.53g,90%)。MS(ESI,neg.):C16H30N4O6计算值,374.2;实测值373.0(M-H)。
步骤8:Boc-缬氨酸-瓜氨酸-氨基-4-苄氨基-N-苄氧基氨基甲酸酯(15)
将之前步骤的产物(12,3.08g,8.23mmol)溶解于N,N-二甲基甲酰胺(DMF,30mL,经分子筛干燥)中,经二环己基碳二亚胺(DCC,2.31g,11.2mmol)和1-羟基苯并三唑水合物(HOBt,1.51g,11.2mmol)处理,烧瓶经N2吹扫并在室温下搅拌1小时。然后添加4-氨基-(N-苄氧基羰基)苄胺(14,2.30g,8.97mmol)的DMF(15mL)溶液,另搅拌反应3天,经过烧结玻璃漏斗过滤,且将固体用乙酸乙酯洗涤。滤液经1:1水/饱和NaHCO3(100mL)洗涤,将水层用10%异丙醇/EtOAc萃取三次,然后将合并的有机层用盐水清洗,经过Na2SO4干燥,过滤。在过滤过程中形成了不溶性凝胶,其用甲醇/EtOAc溶解。在真空下浓缩滤液获得粘性的金色凝胶,其经过乙醚(50mL)处理,超声处理,过滤和抽吸-干燥后获得淡黄色固体。产物在330g硅胶柱(0-10%甲醇的二氯甲烷溶液,100mL/min)上经快速柱层析纯化,得到为淡黄色固体的标题化合物(4.07g,81%).MS(ESI,pos.):计算值C31H44N6O7,612.3;实测值613.4(M+H)。
步骤9:Boc-缬氨酸-瓜氨酸-氨基-4-苄胺(16)
将之前步骤的产物(15,3.04g,4.96mmol)和在活性炭上的10%钯(0)(0.286g,0.269mmol)在N2流下经甲醇(50mL)和冰醋酸(0.57mL,9.95mmol)处理,所述反应经N2鼓泡数分钟后经氢气鼓泡数分钟,然后在氢气球下常温常压大力搅拌1小时。当通过TLC监测反应完全,去除气球,将悬浮液经N2鼓泡数分钟,并且经过Celite 521过滤。用甲醇洗涤所述Celite,在真空下将滤液蒸干,且残余物用乙醚捣碎(triturated)一次并在高度真空下干燥,获得为白色固体的标题化合物(2.95g,99%)。MS(ESI,pos.):C23H38N6O5计算值,478.3;实测值479.2(M+H)。
步骤10:Boc-缬氨酸-瓜氨酸-氨基-4-苄基异硫氰酸酯(17)
在N2环境下,将之前步骤的产物(16,0.586g,0.979mmol)溶解于干燥的四氢呋喃(20mL)和干燥的N,N-二甲基甲酰胺(5mL)中,经过三乙胺(0.40mL,2.87mmol)处理,在冰浴中冷却,并且经过二硫化碳(0.10mL,1.66mmol)逐滴处理5min。将反应物升温至室温并搅拌2小时,再次在冰中冷却,然后经对甲苯磺酰氯(0.281g,1.47mmol)处理。在升温至室温和搅拌18小时后,反应物经过1:1水/盐水洗涤,再经过乙酸乙酯萃取2次,水层用NaCl饱和,再经EtOAc萃取2次,然后将合并的有机层经盐水洗涤,Na2SO4干燥,过滤。在与二氯甲烷共沸和在高度真空下干燥后,将经过蒸发的滤液在20g硅胶柱(0-100%乙腈的EtOAc溶液,35mL/min)上经快速柱层析纯化,得到为金色固体的标题化合物(0.391g,77%)。MS(ESI,pos.):C24H36N6O5S计算值,520.3;实测值521.1(M+H).
步骤11:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺基-3-N-[4-(氨基-瓜氨酸-Boc-缬氨酸)-苄基]-二硫代氨基甲酸酯(18)
在Ar环境下,将之前步骤的产物(17,0.068g,0.131mmol)和美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺-3-硫醇(10,0.048g,0.065mmol)溶解于干燥的THF(3mL)中,通过注射器经三乙胺(0.050mL,0.359mmol)处理且在橡胶隔片下室温搅拌反应18小时。在真空下浓缩反应物,溶解于10%异丙醇/乙酸乙酯中,并经过0.5N的HCl水溶液洗涤。水层经10%IPA/EtOAc溶液萃取3次,将合并的有机层经盐水洗涤,Na2SO4干燥,过滤。浓缩的滤液在12g硅胶柱(0-20%甲醇的EtOAc溶液,30mL/min)上经快速柱层析纯化,获得为白色固体的标题化合物(0.042g,51%)。MS(ESI,pos.):C59H84ClN9O15S2计算值,1257.5;实测值1258.8(M+H),1241.5(M-H2O+H),1280.6(M+Na)。
步骤12:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺基-3-N-[4-(氨基-瓜氨酸-缬氨酸)-苄基]-二硫代氨基甲酸酯(19)
通过使用实施例2步骤3(化合物6)的方法由之前步骤的产物(18,0.014g,0.011mmol)制备出为金色固体的标题化合物(0.016g,100%)。所述化合物没有经过进一步纯化而被使用。MS(ESI,pos.):C54H76ClN9O13S2计算值,1157.5;实测值1159.4(M+H)。
步骤13:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺基-3-N-[4-(氨基-瓜氨酸-缬氨酸-己酰胺-6-马来酰亚胺基)苄基]-二硫代氨基甲酸酯(21)
将之前步骤的产物(19,0.055g,0.032mmol)溶解于1:1乙腈/水(4mL)中,经过1NNaHCO3水溶液(0.5mL)和6-马来酰亚胺基己酸琥珀酸酯(20,0.070g,2.27mmol)的乙腈(6mL)溶液处理,且在橡胶隔片下经Ar吹扫烧瓶。在室温下搅拌反应5小时后,在反应物再次升温至室温和经盐水稀释前将其在-20℃储存3天。混合物经过乙酸乙酯萃取3次,将合并的有机层经Na2SO4干燥,过滤。将经过蒸发的滤液在12g硅胶柱(0-20%甲醇的EtOAc溶液,经18min,25mL/min)上经快速柱层析纯化,得到为淡黄色固体的标题化合物(0.011g,26%).MS(ESI,pos.):C64H87ClN10O16S2,计算值1350.5;实测值1352.0(M+H),1334.5(M-H2O+H),1373.5(M+Na)。
Maytan:美登素
L-Citrulline:L-瓜氨酸
then:然后
实施例4
步骤1:N-(4-氨甲基-苯基)-乙酰胺盐酸盐(23)
通过使用King等(J.Am.Chem.Soc.,1992,114(8),3033)中所描述的方法由4-氨基苄胺制备出标题的浅黄色固体化合物。1H NMR(300MHz,DMSO-d6):δ10.18(s,1H),8.36(brs,3H),7.63(d,2H,J=8.7Hz),7.41(d,2H,J=8.7Hz),3.95(s,2H),2.06(s,3H)。
步骤2:N-(4-异硫氰酸甲酯基-苯基)-乙酰胺(N-(4-Isothiocyanatomethyl-phenyl)-acetamide)(24)
将之前步骤的产物(23,0.277g,1.38mmol)溶解于THF(4.5mL)和DMF(2.0mL)中,N2环境下在冰中冷却,再经三乙胺(0.66mL,4.73mmol)处理,然后用二硫化碳(0.125mL,2.07mmol)逐滴处理。将反应升温至室温,搅拌3小时,然后再次在冰中冷却。在经过对甲苯磺酰氯(0.274g,1.45mmol)处理后,将反应物缓慢升温至室温,搅拌18小时。用水稀释混合物,用10%HCl水溶液将其酸化至pH=2,然后经EtOAc萃取3次。将合并的有机层经盐水洗涤,Na2SO4干燥,过滤。将经过蒸发的滤液在20g硅胶柱(0-50%乙腈的EtOAc溶液,经20min,30mL/min)上经快速柱层析纯化,获得为米白色固体的标题化合物(0.157g,55%)。1H NMR(300MHz,CDCl3)δ7.55(d,2H,J=8.7Hz),7.29(m,3H),4.70(s,2H),2.23(s,3H)。
步骤3:美登素-3-N-甲基-L-(S)-丙氨酸-丙酰胺基-3-N-[4-(乙酰胺基)苄基]-二硫代-氨基甲酸酯(25)
将之前步骤的产物(24,0.093g,0.45mmol)和实施例3步骤3的产物(10,0.070g,0.095mmol)溶解于乙腈(MeCN,2mL)和干燥的DMF(1mL)中,并经过碱性氧化铝(活化的,Brockmann I,0.357g)处理。在用氩气吹扫烧瓶后,在室温下搅拌反应物2天,过滤,且固体经过甲醇/乙腈洗涤,将经过蒸发的滤液在12g硅胶柱(0-50%乙腈的EtOAc溶液,经15min,25mL/min)上经快速柱层析纯化并且在真空下浓缩较慢的产物级分,获得不纯的淡黄色胶状物。将其经过RP-HPLC(Phenomenex Gemini C18,30x150mm柱,30–90%乙腈水溶液,在乙腈和水中的0.1%TFA)纯化,且将纯化的级分冻干后得到为白色固体的标题化合物(0.016g,18%)。MS(ESI,pos.):C45H58ClN5O11S2计算值,943.3;实测值944.7(M+H),927.1(M-H2O+H),966.6(M+Na)。
“King et al”:King等
“Alumina”:氧化铝
“then”:然后
实施例5
美登素-3-N-甲基-L-(S)-丙氨酸-β-丙氨酸(27)
通过实施例2步骤1-3的方法由3-((叔丁基-丁氧基羰基)氨基)丙酸2,5-二氧代吡咯烷-1-基酯(26)制备出标题的浅黄色固体化合物。MS(ESI,pos.):C35H49ClN4O10计算值,720.3;实测值721.4(M+H)。
“water”:水
实施例6
美登素-3-N-甲基-L-(S)-丙氨酸-γ-氨基丁酰胺(29)
通过实施例2步骤1-3的方法由N-Boc-GABA-OH(28)制备出标题的浅黄色固体化合物。MS(ESI,pos.):C36H51ClN4O10计算值,734.3;实测值735.5(M+H)。
“water”:水
实施例7
美登素-3-N-甲基-L-(S)-丙氨酸-N-Me-γ-氨基丁酰胺(31)
通过实施例2步骤1-3的方法由N-Boc-N-Me GABA-OH(30)制备出标题的浅黄色固体化合物。MS(ESI,pos.):C37H53ClN4O10计算值,748.4;实测值749.5(M+H)。
“water”:水
实施例8
步骤1:美登素-3-N-甲基-L-(S)-丙氨酸-N-羧基-6-[3,4-二氢-2-(叔丁氧基羰基)-1H-异喹啉]
将美登素-3-N-甲基-L-(S)-丙氨酸(2,0.034g,0.052mmol)、商用N-Boc-1,2,3,4-四氢异喹啉-6-羧酸(32,0.019g,0.069mmol)和1-(3-二甲基氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC,0.024g,0.125mmol)称入具有搅拌棒的圆底烧瓶中,溶解于二氯甲烷(3mL)中,用Ar清扫烧瓶并且经橡胶隔片密封,将反应物在室温下搅拌。2天后,反应物用EtOAc稀释并经过稀释的NaHCO3水溶液洗涤,且水层用EtOAc萃取2次。将合并的有机层经过盐水洗涤,经过Na2SO4干燥,过滤。然后将经过蒸发的滤液在12g RediSep Gold硅胶柱上经过ISCO系统(EtOAc-5:5:1EtOAc/DCM/MeOH,经12mins,30mL/min)进行纯化,并且在真空下将合并的TLC-纯级分蒸干,得到为白色固体的标题化合物(0.026g,55%)。MS(ESI,pos.):C47H61ClN4O12计算值,908.4;实测值909.2(M+H),891.2(M-H2O+H)。
步骤2:美登素-3-N-甲基-L-(S)-丙氨酸-N-羧基-6-(1,2,3,4-四氢异喹啉)(33)
通过实施例2步骤3(化合物6)的方法由之前步骤的产物(0.025g,0.027mmol)制备出标题的白色固体化合物(0.013g,52%)。MS(ESI,pos.):C42H53ClN4O10计算值,808.3;实测值809.2(M+H)。
“water”:水
实施例9
步骤1:美登素-3-N-甲基-L-(S)-丙氨酸-N-羧基-4-[1-(叔丁氧基羰基)-哌啶]
通过实施例8步骤1的方法由美登素-3-N-甲基-L-(S)-丙氨酸(2,0.045g,0.069mmol)和商用1-叔丁氧基羰基哌啶-4-羧酸(34,0.024g,0.105mmol)制备出标题的白色固体化合物(0.027g,46%)。MS(ESI,pos.):C43H61ClN4O12计算值,860.4;实测值861.2(M+H),843.2(M-H2O+H)。
步骤2:美登素-3-N-甲基-L-(S)-丙氨酸-N-羧基-4-哌啶(35)
通过实施例2步骤3(化合物6)的方法由之前步骤的产物(0.025g,0.029mmol)制备出标题的白色固体化合物(0.012g,50%)。使用不同的梯度和改性剂(20-80%MeCN的水溶液,0.05%的在MeCN和水中的醋酸)在C18柱上纯化所述化合物。将纯化的级分冻干后得到标题化合物(0.008g,35%)。MS(ESI,pos.):C38H53ClN4O10计算值,760.3;实测值761.2(M+H)。
“water”:水
实施例10
步骤1:美登素-3-N-甲基-L-(S)-丙氨酸-N-甲基-β-丙氨酸-N-[4-(叔丁氧基羰基-缬氨酸-瓜氨酸-氨基)苄氧基]-氨基甲酸酯
根据WO 2005112919制备的化合物Boc-缬氨酸-瓜氨酸-对-氨基苄氧基-(对-硝基苯氧基)-碳酸酯(36)(0.092g,0.143mmol)、实施例2步骤3的产物(6,0.110g,0.130mmol)和1-羟基-7-氮杂苯并三氮唑(HOAT,0.037g,0.272mmol)溶解于DMF(7mL)中,经过三乙胺(0.100mL,0.717mmol)处理并且在已塞紧的烧瓶中常温搅拌。18小时后,将反应混合物在真空下浓缩至油状物,溶解于二氯甲烷中,并且在24g RediSep Gold柱上经过ISC℃ombiflash(0–20%的在乙酸乙酯中的甲醇)进行纯化。在真空下蒸发所述产物级分,然后得到为淡黄色固体的标题化合物(0.129g,80%)。MS(ESI,pos.):C60H86ClN9O17计算值,1239.6;实测值1240.8(M+H)。
步骤2:美登素-3-N-甲基-L-(S)-丙氨酸-N-甲基-β-丙氨酸-N-[4-(缬氨酸-瓜氨酸-氨基)苄氧基]-氨基甲酸酯(37)
通过实施例2步骤3(化合物6)的方法由之前步骤的产物(0.128g,0.103mmol)制备出标题的白色固体化合物(0.074g,63%)。MS(ESI,pos.):C55H78ClN9O15计算值,1139.5;实测值1141.4(M+H)。
步骤3:美登素-3-N-甲基-L-(S)-丙氨酸-N-甲基-β-丙氨酸-N-[4-(4-{硫代异氰酸苯酯基}-硫脲基-缬氨酸-瓜氨酸-氨基)苄氧基]-氨基甲酸酯(39)
在小瓶里,将之前步骤的产物(37,0.037g,0.029mmol)溶解于四氢呋喃(THF,5mL)中,经过三乙胺(0.020mL,0.143mmol)处理,并且用15min将产生的溶液逐滴添加至烧瓶中,所述烧瓶装有经搅拌的1,4-亚苯基二异硫氰酸酯(38,0.055g,0.286mmol)的THF(10mL)溶液。所述小瓶经过THF(2mL)漂洗并且将漂洗液添加至反应烧瓶中,将烧瓶用橡胶隔片密封。在室温下搅拌24小时后,在真空下将反应物浓缩至干燥,将粗产物溶解于乙腈中,并经过0.45um PTFE膜过滤。然后将滤液在30g C18RediSep Gold柱经过ISCO(20–80%MeCN的水溶液,在MeCN和水中的0.05%HOAc)纯化,并将最纯的级分(通过LC)合并,在-78℃下冷冻,并且冻干得到标题的白色固体化合物(0.023g,59%)。MS(ESI,pos.):C63H82ClN11O15S2计算值,1331.5;实测值1332.0(M+H)。
“water”:水
实施例11
步骤1:1-(4-氨基-丁基)-马来酰亚胺
商用Boc-1-氨基丁基-4-马来酰亚胺(0.304g,1.13mmol)的二氯甲烷(10mL)溶液经过三氟乙酸(1.00mL,13.1mmol)处理,用Ar吹扫烧瓶,用橡胶隔片和鼓泡器通气管(bubbler vent)密封,且在室温下搅拌。18小时后通过TLC确定反应完全,所以将其在真空下浓缩,用乙醚研磨2次,在真空下干燥至胶状。用醚再研磨产物2次(用抹刀刮下),轻轻倒出,并且再次在真空下干燥,得到标题的白色固体化合物(0.321g,100%)。MS(ESI,pos.):C8H12N2O2计算值,168.1;实测值169.0(M+H)。
步骤2:1-(4-异氰酸丁酯基)-马来酰亚胺(41)
将之前步骤的产物溶解于乙腈(MeCN,3x 40mL)中,且在60℃下通过旋转蒸发仪真空浓缩。在烧瓶中,将得到的干燥产物(0.650g,2.45mmol)溶解于MeCN(75mL)和氯仿(30mL)中,经过三乙胺(1.0mL,7.35mmol)处理,在氮气环境下,用10min的时间,将反应产生的溶液逐滴加入装有1,1'-硫代羰基二-2,2'-吡啶酮(0.68g,2.94mmol)的氯仿(25mL)溶液的烧瓶中。反应在室温下搅拌18小时,在真空下将反应物浓缩至干燥,粗产物溶解于二氯甲烷(DCM)中,并且在120g硅胶RediSep Gold柱上经过快速柱层析(0-10%MeOH的DCM溶液)纯化。将最纯净的级分(通过LC)合并,并且浓缩至干燥,得到标题的白色固体化合物(0.26g,50%)。MS(ESI,pos.):C9H10N2O2S计算值,210.0;实测值211.2(M+H)。
步骤3:美登素-3-N-甲基-L-(S)-丙氨酸-N-甲基-β-丙氨酸-N-[4-(4-{马来酰亚胺基丁基}-硫脲基-缬氨酸-瓜氨酸-氨基)苄氧基]-氨基甲酸酯(42)
将实施例10步骤2的产物(37,0.029g,0.023mmol)溶解于干燥的DMF(2mL)中,通过干燥注射器经二异丙基乙基胺(0.020mL,0.115mmol)处理,然后经过之前步骤产物(41,0.026g,0.124mmol)的干燥DMF(2mL)溶液处理。用Ar吹扫反应烧瓶,橡胶隔片密封,且在室温下搅拌反应。通过LCMS,18小时后反应似乎反应了80%,所以将产物在真空下蒸发至油状,溶解于MeCN/水中,并且在30g C18RediSep Gold柱经过快速柱层析(20–80%MeCN的水溶液,在MeCN和水中的0.05%HOAc)纯化。通过LCMS将最纯的级分合并,旋转蒸发仪短暂蒸发,然后在干冰上冷冻,且过夜冷冻获得标题的白色固体化合物(0.020g,65%)。MS(ESI,pos.):C64H88N11O17SCl计算值,1349.6;实测值1351.1(M+H),1372.9(M+Na),1333.6(M-H2O+H)。
实施例12
偶联物的制备与表征
对于最初的实验组,使用如下过程将四个抗体偶联到本发明的各种连接体-药物化合物。在这些实验中使用的四个抗体为:如WO 2007002222A2中所述的具有克隆AB-PG1-XG1-006的重链和轻链可变域的PSMA抗体,(2)如WO 2008052187A2中所述的、表达为hIgG1的、具有克隆mu120的重链和轻链可变域的STEAP1抗体,(3)如WO2013075048A1中所述的具有克隆131的重链和轻链可变域的EGFRvIII抗体,和(4)如美国专利申请序列号61/868,185(申请日:2013年8月21日,在此其公开内容整体通过引用并入本文)中所述的具有克隆H1H6953N的重链和轻链可变域的PRLR抗体。所有的单克隆抗体均在CHO细胞中表达并通过蛋白A纯化。来自与肿瘤学无关的免疫抗原的不受约束的对照也被使用。
化合物3、7、21和42的偶联方法
在37℃下,50mM HEPES、150mM NaCl中的抗体(10mg/ml)(pH=7.5)经1mM二硫苏糖醇处理30min。凝胶过滤之后(G-25,pH 4.5醋酸钠),将DMSO(10mg/ml)中的马来酰亚胺基(maleimido)连接体有效负载衍生物(1.2当量/SH基团)添加至还原的抗体且使用1M HEPES(pH 7.4)将混合物pH调节至7.0。1h后,反应经过量的N-乙基马来酰亚胺淬灭。通过排阻色谱纯化偶联物且经过无菌过滤。蛋白质和连接体有效负载的浓度由UV光谱分析确定。尺寸排阻HPLC确定了使用的所有偶联物是>95%的单体,且RP-HPLC确定了有<0.5%的未偶联的连接体有效负载。表1中以蛋白质计报告了产量。根据Hamblett等,Cancer Res.,2004107063,通过UV分析了所有偶联抗体的连接体有效负载荷载值。结果在表1中进行了总结。
化合物39的偶联方法
在50mM碳酸盐、150mM NaCl的抗体(2-5mg/ml)(pH 9.0)中加入15%(以体积计)的二甲基乙酰胺。将DMSO(10mg/ml)中的连接体有效负载衍生物39(5-10当量)加入抗体中,且混合物在37℃下培养4-12小时。偶联物经过尺寸排阻色谱纯化和无菌过滤。蛋白质和连接体有效负载的浓度由UV光谱分析确定。尺寸排阻HPLC确定了使用的所有偶联物是>95%的单体,且RP-HPLC确定了有<0.5%的未偶联的连接体有效负载。对于这些偶联物,有效负载-抗体比由MALDI-TOF确定(表1)。
表1
实施例13
体外抗体-药物偶联物(ADC)无细胞酶法测定
组织蛋白酶B培养
体外无细胞酶法测定的过程选自Dubowchik等,Bioconjugate Chem. 2002 13855。DAR修正的PRLR-7和同种型对照-7浓度设置为在25mM醋酸钠缓冲液、1mM EDTA中为7.00uM(pH=5.0)并且在37℃下预培养。在室温下活化组织蛋白酶B(Sigma#C8571)15min,其中1当量的30mMDTT、15mM EDTA对应2当量的组织蛋白酶B原液。将激活的组织蛋白酶B溶液以1:750的摩尔比添加至ADC溶液中。样品在37℃下培养24小时,并且针对HPLC(HISEP)-UV检测或LC-MS检测参见下文来进行等分。
LC-MS检测
在指定的时间点,取小的等分试样并且与2当量(按体积计)的冷甲醇合并。回收上层清液且通过液相色谱-质谱(LCMS)分析组织蛋白酶B连接体有效负载裂解产生的化合物6,所述LCMS使用Merck Chromolith FastGradient RP-18e,2x50mm柱(在水中的10-90%MeCN,经5mins,在两种溶剂中的0.05%HOAc,且流速为1mL)。在254nm下监测洗脱图谱。以组织蛋白酶B在37℃培养的所有等份样品含有化合物6,该化合物6在第5.1分钟洗脱,质量为735M+H(C36H51ClN4O10计算值,734.3),且没有组织蛋白酶B的等份样品均不含有任何化合物6。这也通过注入来自实施例2步骤3的纯化合物6得以确认。
HPLC(HISEP)-UV检测
在指定的时间点,“按原样”注入溶液。利用以下梯度方法:缓冲液A100%100mMNH4OAc,pH 7.0和缓冲液B 100%乙腈,流速0.4mL/min,从5至70%的缓冲液B,使用SupelcoLC-HISEP;150mm x 4.6mm,柱。在280nm和252nm监测洗脱图谱。组织蛋白酶B的所有等份样品培养的ADC含有在19.4分钟洗脱的物质。在相同的梯度条件下,纯化合物6在相同的保留时间下洗脱。19.4分钟的物质没有存在于没有组织蛋白酶B的等份样品中。
在某种程度上这个例子的结果是重要的,因为化合物6的组织蛋白酶B的蛋白酶水解仅应该发生ADC在细胞内的内化之后,所述的细胞中存在有酶。脱靶效应应减少,因为抗体将细胞毒性有效负载直接递送给靶细胞。
实施例14
体外细胞毒试验
在本例中,评估了各种抗体-药物偶联物在体外杀死表达抗原的肿瘤细胞的能力。
将细胞接种于PDL-涂覆的96孔板内并过夜生长,所述接种在完全生长培养基中以375(MMT/hEGFRvIII)、1500(U251/hEGFRvIII)、2000(HEK293/hEGFRvIII)或3000(C4-2,PC3/hSTEAP1,T47D和U87-MG)细胞每孔。对于细胞活力曲线,将系列稀释的偶联物或游离的代表性有效负载以500nM至1pM的最终浓度添加至细胞中并培养3天。为了测量MMT/hEGFRvIII、U251/hEGFRvIII、HEK293/hEGFRvIII、C4-2、PC3/hSTEAP1和U87-MG的存活力,将细胞与CCK8(Dojindo)一起培养最后1-3小时,且在Flexstation3(Molecular Devices)上在450nm(OD450)处测定其吸光度。为了测量T47D的存活力,将细胞在4%福尔马林+3ug/mlHoechst中在冰上培养30min。Hoechst染色的细胞核图像在ImageXpress Micro XL(Molecular Devices)上获得,且细胞核的数量由Columbus分析软件(PerkinElmer)确定。经洋地黄皂苷(40nm)处理的细胞的背景OD450水平(CCK8)或细胞核数量从所有孔减去,并且活力表示为未经处理的对照组的百分比。由四参数逻辑斯谛方程在10-点响应曲线(GraphPad Prism)上确定IC50值。所有的曲线和IC50值针对有效负载当量进行修正。
在C4-2细胞(前列腺癌细胞系)中,该细胞天然表达的PSMA超过同种型对照结合的271倍,美登木素生物碱偶联物PSMA-3、PSMA-7和PSMA-21具有的IC50值分别为3.8、0.5和8.3nM(图1)。裸PSMA抗体缺乏任何抗增殖活性。
在PC3/hSTEAP1细胞(前列腺癌细胞系)中,该细胞表达的hSTEAP1超过同种型对照结合的352倍,美登木素生物碱偶联物STEAP1-7具有的IC50值为4nM(图2)。裸STEAP1抗体缺乏任何抗增殖活性。
在T47D细胞(乳腺癌细胞系)中,该细胞天然表达的PRLR超过同种型对照结合的14倍,美登木素生物碱偶联物PRLR-7具有的IC50值为1.0nM(图3)。裸T47D抗体缺乏任何抗增殖活性。
在HEK293/hEGFRvIII细胞中,该细胞表达的hEGFRvIII超过同种型对照结合的360倍,美登木素生物碱偶联物EGFRvIII-7具有的IC50值为0.4nM(图4)。裸EGFRvIII抗体缺乏任何抗增殖活性。
在MMT/hEGFRvIII细胞中,该细胞表达的hEGFRvIII超过同种型对照结合的280倍,美登木素生物碱偶联物EGFRvIII-7具有的IC50值为0.3nM(图5)。裸EGFRvIII抗体缺乏任何抗增殖活性。
在U251/hEGFRvIII细胞(恶性胶质瘤癌细胞系)中,该细胞表达的hEGFRvIII超过同种型对照结合的165倍,美登木素生物碱偶联物EGFRvIII-7具有的IC50值为0.3nM(图6)。裸EGFRvIII抗体缺乏任何抗增殖活性。
提出的释放的有效负载(“游离药物”)的体外细胞毒性也在以上描述的各种细胞系中测试并且为了进行对比,沿侧绘制了偶联的抗体(见图1至图6中的实心方块(■))。对于连接体-有效负载3和7,提出的释放的有效负载2和6可分别直接用于细胞分析因为他们是稳定的。然而,对于连接体-有效负载21,提出的释放有效负载是巯基化合物10。由于化合物10可以是非常有活性的化合物,这将导致不可靠的结果,在这些试验中选择化合物25来代表释放的有效负载。
在分开的实验组中,在HEK293和U87MG中测试化合物6同氨基类似物27、29和31的抗增殖活性(图7)。这些化合物均具有>30nM的IC50值,这表明仅当通过适当的连接体连接到抗体时,它们是高细胞毒性的。(这些实验不用洋地黄皂苷进行背景校正)。
在另一组实验中,在HEK293、U251、C4-2、PC3和MMT中测试化合物6、9、33、和35的抗增殖活性(图8)。氨基化合物6、33和35具有不同的IC50值,如表2所列。效力趋势遵照9>33>35>6,且对于5个细胞系试验,该效力趋势是一致的。
表2
不受任何理论的约束,这些实验的结果表明,在大多数情况下,本发明的化合物的“释放”或“游离药物”形式(即,不与抗体偶联的化合物)实质上比在偶联到靶向抗体时的细胞毒性低。本发明的这个特点表明,包括本发明化合物的抗体-药物偶联物将导致更少的副作用和更少的不希望的毒性,这是因为细胞杀伤性能将在靶抗原位点特异性集中。
实施例15
抗EGFRvIII抗体药物偶联物是体内EGFRvIII阳性乳腺癌同种异体移植模型中有效的肿瘤生长抑制剂
在这个例子中,测试了典型的抗EGFRvIII抗体H1H1863N2的两个不同的抗体-药物偶联物在体内抑制肿瘤生长的能力。(H1H1863N2的氨基酸序列和不同性能在US 61/950,963中阐述,申请日为2014年3月11日,在此其整体通过引用并入本文)。H1H1863N2包括重链可变区(HCVR)(包括序列号:1);轻链可变区(LCVR)(包括序列号:5);重链互补决定区(HCDR1、HCDR2和HCDR3)(分别包括序列号:2、3和4);和轻链互补决定区(LCDR1、LCDR2和LCDR3)(分别包括序列号:6、7和8)。
第一ADC是通过不可切割的MCC连接体(参见,例如,US 5,208,020和美国申请号20100129314)将H1H1863N2与美登木素生物碱DM1偶联以产生“H1H1863N2-MCC-DM1”而产生的。第二ADC是通过将H1H1863N2与化合物7偶联以产生“H1H1863N2-7”而产生的。当使用实施例14中所描述的测试方式来测试对MMT/EGFRvIII细胞的体外细胞毒性时,H1H1863N2-MCC-DM1显示出的IC50值为12nM,而H1H1863N2-7显示出的IC50值仅为0.8nM。因此,在体外,抗EGFRvIII ADC H1H1863N2-7比相应的通过MCC连接体与DM1偶联的抗体具有更强的肿瘤细胞杀伤能力。
为了比较偶联到MCC-DM1和化合物7的抗EGFRvIII抗体的体内有效性,对具有EGFRvIII阳性乳腺癌同种异体移植物的免疫力低下的小鼠进行了研究。简而言之,通过将0.5x106MMT/EGFRvIII细胞经皮下植入到雌性CB17SCID小鼠(Taconic,Hudson,NY)的左胁腹中而建立肿瘤同种异体移植物。一旦肿瘤达到了140mm3(~8天)的平均体积,小鼠随机分为七组,并按剂量施用使用MCC-DM1或7的连接体-药物形式的抗EGFRvIII ADC们。对照试剂和PBS媒介物也被进行了评估,所述对照试剂包括使用MCC-DM1或7的连接体-药物格式的非结合的ADC们。ADC们的剂量为1和5mg/kg,在一周内施用三次,此后一直监测,直到在只施用媒介物的组中达到约2000mm3的平均肿瘤尺寸。在这时候计算肿瘤生长抑制。
关于经媒介物处理的组的平均肿瘤尺寸计算如下:肿瘤用卡尺一周测量两次,直到媒介物组的平均尺寸达到1000mm3;利用公式(长x宽2)/2计算肿瘤尺寸。根据下列公式计算肿瘤生长抑制:(1-((T最终-T初始)/(C最终-C初始)))*100,其中T(处理组)和C(对照组)代表在媒介物组达到1000mm3的当天的平均肿瘤质量。总结的结果见表3。
表3:施用以重复剂量施用的抗EGFRvIII抗体-药物偶联物和对照物后的肿瘤尺寸及肿瘤生长抑制
如本例所示,在小鼠服用了5mg/kg H1H1863N2-7后观察到最大的肿瘤抑制,其中观察到初始肿瘤的消退。用5mg/kg H1H1863N2-7处理导致了102%的肿瘤生长抑制,这相对于观察到的用5mg/kg H1H1862N2-MCC-DM1对肿瘤进行处理后的生长抑制(83%)明显更大。由H1H1863N2-7诱导的肿瘤生长抑制的优势与H1H1863N2-MCC-DM1相比也维持在1mg/kg的剂量。在使用MCC-DM1或7的对照ADC处理后的组中未观察到抗肿瘤作用。
Claims (23)
1.具有如下式的化合物
其中;
Ab是抗体或其抗原结合片段,能够结合细胞或细胞群;
a是从1到10的整数;
A是天然或非天然氨基酸残基,或包括2-5个氨基酸残基的肽残基;
A3是-CH2-,-CH2CH2-或-CH2CH2CH2CH2-;
R1是氧;
R17是氧;
R4是氢;
R4a是烷基;
q是1-5的整数;和
R9、R10、R11和R12是氢。
2.根据权利要求1所述的化合物,其中Ab能够结合到特异性靶细胞群。
3.根据权利要求1所述的化合物,其中Ab是特异性结合肿瘤相关抗原的抗体或其抗原结合片段。
4.根据权利要求1所述的化合物,其中A是氨基酸残基,所述氨基酸选自如下氨基酸所构成的组:丙氨酸、天冬氨酸、谷氨酸、苯丙氨酸、甘氨酸、组氨酸、异亮氨酸、赖氨酸、亮氨酸、蛋氨酸、天冬酰胺、脯氨酸、谷氨酰胺、精氨酸、丝氨酸、苏氨酸、缬氨酸、色氨酸、酪氨酸、半胱氨酸和瓜氨酸残基。
5.根据权利要求1所述的化合物,其中A是缬氨酸-瓜氨酸肽残基。
6.根据权利要求1所述的化合物,其中q是4。
7.根据权利要求1所述的化合物,所述化合物具有如下结构:
其中Ab是抗体或其抗原结合片段。
8.根据权利要求1所述的化合物,其中A是蛋白酶可切割的肽残基。
9.根据权利要求1所述的化合物,其中A是在肿瘤组织中表达的蛋白酶可切割的肽残基。
10.根据权利要求9所述的化合物,其中所述蛋白酶是组织蛋白酶或纤溶酶。
11.具有如下式的化合物
其中:
Ab是抗体或其抗原结合片段,能够结合细胞或细胞群;
a是从1到10的整数;
A是天然或非天然氨基酸残基,或包括2-5个氨基酸残基的肽残基;
A3是-CH2-,-CH2CH2-或-CH2CH2CH2CH2-;
R1是氧;
R17是氧;
R4是氢;
R4a是烷基;
q是1-5的整数;和
R9、R10、R11和R12是氢。
12.根据权利要求11所述的化合物,所述化合物具有如下结构:
其中a是1-10的整数。
13.药物组合物,所述药物组合物包含
治疗上有效量的权利要求1中所述的化合物或其药学上可接受的盐
以及
一种或多种药学上可接受的赋形剂。
14.药物组合物,所述药物组合物包含
治疗上有效量的权利要求1中所述的化合物或其药学上可接受的盐
以及
一种或多种药学上可接受的稀释剂。
15.权利要求1中所述的化合物在制备用于减少、延缓或阻止异常细胞生长的药物中的应用,所述应用包括使所述异常细胞与权利要求1中所述的化合物接触,所述化合物具有足以延缓、减少或阻止所述异常细胞生长的量,并且其中所述异常细胞生长被延缓、减少或阻止,所述异常细胞包括肺癌、结肠癌、前列腺癌、肾癌、胰腺癌、肝癌、卵巢癌、皮肤癌、淋巴癌、白血病、乳腺癌和恶性胶质瘤中的一种或几种。
16.权利要求1中所述的化合物在制备用于杀死肿瘤细胞的药物中的应用,所述应用包括使所述肿瘤细胞与权利要求1中所述的化合物接触,所述化合物具有足以杀死所述肿瘤细胞的量,并且其中所述肿瘤细胞被杀死,其中所述肿瘤细胞包括肺癌、结肠癌、前列腺癌、肾癌、胰腺癌、肝癌、卵巢癌、皮肤癌、淋巴癌、白血病、乳腺癌和恶性胶质瘤中的一种或几种。
17.权利要求1中所述的化合物在制备用于在有需要的个体中减小肿瘤尺寸、阻止肿瘤尺寸增加、减少肿瘤增殖、或防止肿瘤增殖的药物中的应用,所述应用包括将有效量的组合物施用至所述个体以减小肿瘤尺寸、阻止肿瘤尺寸增加、减少肿瘤增殖、或防止肿瘤增殖,其中所述组合物包含权利要求1中所述的化合物,所述肿瘤包括肺癌、结肠癌、前列腺癌、肾癌、胰腺癌、肝癌、卵巢癌、皮肤癌、淋巴癌、白血病、乳腺癌和恶性胶质瘤中的一种或几种。
18.具有选自以下结构组成的组的结构的化合物:
19.具有如下式的化合物:
其中:
A3是-CH2-,-CH2CH2-或-CH2CH2CH2CH2-;
R4a是烷基。
20.根据权利要求19所述的化合物,所述化合物具有如下结构:
21.具有如下式的化合物
其中:
Ab是抗体或其抗原结合片段;和
a是1-10的整数。
22.具有选自以下结构组成的组的结构的化合物:
23.包含抗体或抗原结合片段偶联到如下式的有效负载的抗体-药物偶联物:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792216P | 2013-03-15 | 2013-03-15 | |
US61/792,216 | 2013-03-15 | ||
PCT/US2014/029757 WO2014145090A1 (en) | 2013-03-15 | 2014-03-14 | Biologically active molecules, conjugates thereof, and therapeutic uses |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105188766A CN105188766A (zh) | 2015-12-23 |
CN105188766B true CN105188766B (zh) | 2019-07-12 |
Family
ID=50933481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480025356.9A Active CN105188766B (zh) | 2013-03-15 | 2014-03-14 | 生物活性分子、其偶联物及治疗用途 |
Country Status (19)
Country | Link |
---|---|
US (3) | US10570151B2 (zh) |
EP (2) | EP3964237A1 (zh) |
JP (3) | JP6847388B2 (zh) |
KR (1) | KR102306490B1 (zh) |
CN (1) | CN105188766B (zh) |
AU (1) | AU2014233385C1 (zh) |
BR (1) | BR112015022585B1 (zh) |
CA (1) | CA2902872A1 (zh) |
CL (1) | CL2015002765A1 (zh) |
EA (1) | EA038512B1 (zh) |
HK (1) | HK1212890A1 (zh) |
IL (1) | IL240418B (zh) |
MA (1) | MA38496B2 (zh) |
MX (1) | MX2015011348A (zh) |
MY (1) | MY183572A (zh) |
PH (1) | PH12015502131B1 (zh) |
SG (1) | SG11201507481WA (zh) |
WO (1) | WO2014145090A1 (zh) |
ZA (1) | ZA201505813B (zh) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8542802B2 (en) | 2007-02-15 | 2013-09-24 | Global Tel*Link Corporation | System and method for three-way call detection |
KR20150119848A (ko) | 2012-12-21 | 2015-10-26 | 바이오얼라이언스 씨.브이. | 친수성 자기-희생 링커 및 그것의 포합체 |
EP3964237A1 (en) | 2013-03-15 | 2022-03-09 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
MX2016002149A (es) | 2013-08-26 | 2016-10-28 | Regeneron Pharma | Composiciones farmaceuticas que contienen diasteromeros macrolidos, metodos para su sintesis y usos terapeuticos. |
MX2016011619A (es) | 2014-03-11 | 2016-12-12 | Regeneron Pharma | Anticuerpos anti-egfrviii y usos de los mismos. |
US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
JP2017528418A (ja) | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
CN107995912A (zh) * | 2015-03-27 | 2018-05-04 | 里珍纳龙药品有限公司 | 美登素类衍生物、其偶联物和使用方法 |
EP3308801A4 (en) | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | ANTIBODY-MEDICINAL CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
US11129903B2 (en) | 2015-07-06 | 2021-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
MX2018008144A (es) | 2016-01-08 | 2018-11-09 | Bioalliance Cv | Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos. |
AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
RS64691B1 (sr) | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom |
MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
JP7174699B2 (ja) | 2016-11-29 | 2022-11-17 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Prlr陽性乳癌の治療方法 |
WO2018129384A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
CN110475569B (zh) | 2017-02-28 | 2023-11-21 | 第一三共株式会社 | Egfr-tki耐受性的非小细胞肺癌的治疗剂以及抗her3抗体-药物偶联物的应用 |
TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗-prlr抗體藥物軛合物(adc)及其用途 |
IL270594B2 (en) | 2017-05-18 | 2024-06-01 | Regeneron Pharma | Protein conjugates - a drug of cyclodextrin |
EP3641830A1 (en) | 2017-06-23 | 2020-04-29 | Velosbio Inc. | Ror1 antibody immunoconjugates |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
CA3077213A1 (en) | 2017-10-04 | 2019-04-11 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
CN111601619A (zh) * | 2017-11-07 | 2020-08-28 | 里珍纳龙药品有限公司 | 用于抗体药物偶联物的亲水性连接体 |
MX2020005860A (es) | 2017-12-06 | 2020-09-09 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica. |
WO2019212965A1 (en) | 2018-04-30 | 2019-11-07 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
SG11202011232VA (en) | 2018-05-17 | 2020-12-30 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
CA3104511A1 (en) * | 2018-06-26 | 2020-01-02 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
US20220072144A1 (en) | 2018-09-20 | 2022-03-10 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
TW202039573A (zh) | 2018-12-21 | 2020-11-01 | 美商亞維代堤生物科學公司 | 抗轉鐵蛋白受體抗體及其用途 |
CA3128519A1 (en) | 2019-02-21 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
CA3142283A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
US12006499B2 (en) | 2019-06-06 | 2024-06-11 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
JP2022547274A (ja) | 2019-09-16 | 2022-11-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫pet撮像のための放射標識されたmet結合タンパク質 |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
KR20220115566A (ko) | 2019-11-15 | 2022-08-17 | 시아겐 인크. | 항-her2 항체-약물 접합체와 조합된 투카티닙으로 her2 양성 유방암을 치료하는 방법 |
BR112022014278A2 (pt) | 2020-01-24 | 2022-09-20 | Regeneron Pharma | Conjugados de composto proteico-antiviral |
US11958910B2 (en) | 2020-02-28 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
JP2023527638A (ja) | 2020-03-27 | 2023-06-30 | アビディティー バイオサイエンシーズ,インク. | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 |
IL297027A (en) | 2020-04-16 | 2022-12-01 | Regeneron Pharma | Diels-Alder compression methods |
AU2021307257A1 (en) | 2020-07-17 | 2023-03-09 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
AU2021366691B2 (en) | 2020-10-22 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
EP4243876A1 (en) | 2020-11-10 | 2023-09-20 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
JPWO2022211075A1 (zh) | 2021-03-31 | 2022-10-06 | ||
CA3216175A1 (en) | 2021-04-05 | 2022-10-13 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
EP4401792A1 (en) | 2021-09-16 | 2024-07-24 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2023122347A2 (en) | 2021-12-23 | 2023-06-29 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
WO2023194501A1 (en) | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056626A (zh) * | 2008-04-11 | 2011-05-11 | 西雅图遗传学公司 | 胰腺癌、卵巢癌和其它癌症的检测和治疗 |
CN102573908A (zh) * | 2009-10-23 | 2012-07-11 | 米伦纽姆医药公司 | 抗gcc抗体分子及其相关组合物和方法 |
CA2836927A1 (en) * | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
CN1649625A (zh) * | 2002-03-01 | 2005-08-03 | 图兰恩教育基金管理人 | 治疗剂或细胞毒性剂与生物活性肽的偶联物 |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
AU2004260936B2 (en) | 2003-06-27 | 2010-06-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
CN101948541B (zh) * | 2005-06-20 | 2014-08-06 | 健泰科生物技术公司 | 用于肿瘤诊断和治疗的组合物和方法 |
WO2007002222A2 (en) | 2005-06-20 | 2007-01-04 | Psma Development Company, Llc | Psma antibody-drug conjugates |
ATE535529T1 (de) | 2005-08-09 | 2011-12-15 | Millennium Pharm Inc | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
SI1928503T1 (sl) * | 2005-08-24 | 2012-11-30 | Immunogen Inc | Postopek za pripravo konjugatov majtansinoid protitelo |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
PT2061814E (pt) | 2006-10-27 | 2012-09-10 | Genentech Inc | Anticorpos e imunoconjugados e suas utilizações |
JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
US7723485B2 (en) | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
CA2687178C (en) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
EP3692988A3 (en) | 2008-03-18 | 2020-10-14 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
KR101764081B1 (ko) | 2008-04-30 | 2017-08-01 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
EP2326349B1 (en) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
EP2403538B1 (en) | 2009-03-04 | 2017-10-04 | Polytherics Limited | Conjugated proteins and peptides |
AU2010236787A1 (en) * | 2009-04-01 | 2011-11-10 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
EP2549276B1 (en) | 2009-08-10 | 2015-02-25 | UCL Business PLC | Reversible covalent linkage of functional molecules |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
IN2012DN02780A (zh) | 2009-10-06 | 2015-09-18 | Immunogen Inc | |
US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
EP2528625B1 (en) | 2010-04-15 | 2013-07-10 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
AU2011298424B2 (en) | 2010-09-01 | 2015-05-21 | Bayer Cropscience Aktiengesellschaft | N-(Tetrazol-5-yl)- and N-(Triazol-5-yl)arylcarboxamides and use thereof as herbicides |
CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
CN106349254A (zh) | 2010-11-03 | 2017-01-25 | 伊缪诺金公司 | 包含新型安丝菌素衍生物的细胞毒性剂 |
CN103313990B (zh) * | 2010-11-17 | 2016-07-20 | 基因泰克公司 | 丙氨酰美登醇抗体偶联物 |
CN103732257A (zh) | 2011-05-16 | 2014-04-16 | 皇家飞利浦有限公司 | 生物正交药物活化 |
CA2837167A1 (en) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
PE20141937A1 (es) | 2011-11-16 | 2014-12-18 | Amgen Inc | Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico |
CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
JP2015521615A (ja) | 2012-06-19 | 2015-07-30 | ポリセリックス・リミテッド | 抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート |
EP2911699B1 (en) * | 2012-10-23 | 2017-11-15 | SynAffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
NO2789793T3 (zh) | 2012-10-24 | 2018-01-27 | ||
CN105849086B (zh) | 2012-11-24 | 2018-07-31 | 杭州多禧生物科技有限公司 | 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用 |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
CN104650113A (zh) | 2012-12-21 | 2015-05-27 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
EP3964237A1 (en) | 2013-03-15 | 2022-03-09 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
CA2914369C (en) | 2013-06-06 | 2023-02-14 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
MX2016002149A (es) | 2013-08-26 | 2016-10-28 | Regeneron Pharma | Composiciones farmaceuticas que contienen diasteromeros macrolidos, metodos para su sintesis y usos terapeuticos. |
US20160354105A1 (en) | 2013-11-26 | 2016-12-08 | Segway Orthopaedics, Inc. | Surgical Blade with Viewing Aperture |
JP6745218B2 (ja) | 2013-11-27 | 2020-08-26 | レッドウッド バイオサイエンス, インコーポレイテッド | ヒドラジニル−ピロロ化合物及び複合体を生成するための方法 |
EP3077402B1 (en) | 2013-12-02 | 2018-09-19 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
CN107995912A (zh) | 2015-03-27 | 2018-05-04 | 里珍纳龙药品有限公司 | 美登素类衍生物、其偶联物和使用方法 |
AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2014
- 2014-03-14 EP EP21194635.5A patent/EP3964237A1/en active Pending
- 2014-03-14 SG SG11201507481WA patent/SG11201507481WA/en unknown
- 2014-03-14 CA CA2902872A patent/CA2902872A1/en active Pending
- 2014-03-14 MY MYPI2015002247A patent/MY183572A/en unknown
- 2014-03-14 CN CN201480025356.9A patent/CN105188766B/zh active Active
- 2014-03-14 MA MA38496A patent/MA38496B2/fr unknown
- 2014-03-14 MX MX2015011348A patent/MX2015011348A/es unknown
- 2014-03-14 AU AU2014233385A patent/AU2014233385C1/en active Active
- 2014-03-14 WO PCT/US2014/029757 patent/WO2014145090A1/en active Application Filing
- 2014-03-14 EA EA201500905A patent/EA038512B1/ru unknown
- 2014-03-14 KR KR1020157028418A patent/KR102306490B1/ko active IP Right Grant
- 2014-03-14 BR BR112015022585-3A patent/BR112015022585B1/pt active IP Right Grant
- 2014-03-14 JP JP2016503215A patent/JP6847388B2/ja active Active
- 2014-03-14 US US14/776,668 patent/US10570151B2/en active Active
- 2014-03-14 EP EP14729755.0A patent/EP2968593A1/en active Pending
-
2015
- 2015-08-06 IL IL240418A patent/IL240418B/en active IP Right Grant
- 2015-08-13 ZA ZA2015/05813A patent/ZA201505813B/en unknown
- 2015-09-15 CL CL2015002765A patent/CL2015002765A1/es unknown
- 2015-09-15 PH PH12015502131A patent/PH12015502131B1/en unknown
-
2016
- 2016-01-25 HK HK16100789.7A patent/HK1212890A1/zh unknown
-
2019
- 2019-03-26 JP JP2019059070A patent/JP2019135239A/ja active Pending
-
2020
- 2020-01-10 US US16/740,312 patent/US11345715B2/en active Active
-
2021
- 2021-03-17 JP JP2021043270A patent/JP2021105007A/ja active Pending
-
2022
- 2022-04-29 US US17/733,974 patent/US20220332729A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056626A (zh) * | 2008-04-11 | 2011-05-11 | 西雅图遗传学公司 | 胰腺癌、卵巢癌和其它癌症的检测和治疗 |
CN102573908A (zh) * | 2009-10-23 | 2012-07-11 | 米伦纽姆医药公司 | 抗gcc抗体分子及其相关组合物和方法 |
CA2836927A1 (en) * | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
Non-Patent Citations (2)
Title |
---|
Dipeptide-based highly potent doxorubicin antibody conjugates;Scott C. Jeffrey;《Bioorganic & Medicinal Chemistry Letters》;20061231;第16卷;第360页左栏Scheme 3 |
Scott C. Jeffrey.Dipeptide-based highly potent doxorubicin antibody conjugates.《Bioorganic & Medicinal Chemistry Letters》.2006,第16卷 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105188766B (zh) | 生物活性分子、其偶联物及治疗用途 | |
JP6800021B2 (ja) | 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途 | |
JP7132311B2 (ja) | 細胞障害性ベンゾジアゼピン誘導体 | |
EP3313845B1 (en) | Conjugates of cysteine engineered antibodies | |
KR20200099123A (ko) | 생체활성 접합체, 이의 제조 방법 및 용도 | |
EA039072B1 (ru) | Производные майтанзиноида, их конъюгаты и способы применения | |
TW201116300A (en) | DR5 Ligand Drug Conjugates | |
CN107580604A (zh) | 包含细胞结合剂和细胞毒性剂的缀合物 | |
JP2024511360A (ja) | 生体活性化合物の内部移行複合体からの選択的薬物放出 | |
JP6423804B2 (ja) | 細胞結合剤及び細胞毒性剤を含む複合体 | |
WO2024067754A1 (zh) | 一种带有高稳定性亲水连接单元的奥瑞他汀类药物及其偶联物 | |
WO2023170247A1 (en) | Antibody-drug conjugates and their uses | |
AU2023231442A1 (en) | Antibody-drug conjugates and their uses | |
NZ710814B2 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |